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ABSTRACT 
 
 
 
COMPACT GENE REGULATORY CASSETTES SUPPORT HALLMARK FEATURES OF 
T-CELL RECEPTOR (TCR)-α GENE LOCUS CONTROL REGION (LCR) ACTIVITY 
 
by 
 
JORDANA LOVETT 
 
Advisor: Dr. Ben Ortiz 
 
 
Despite the promise of emerging stem cell transplant gene therapy strategies, there 
remains a gap in the ability to predictably generate robust, temporally controlled long-
lasting, therapeutic gene expression in specific target cell lineages following stem cell 
differentiation. There exists a locus control region (LCR) in the mouse T-cell receptor 
(TCR)-α locus that confers an αβ TCR-like spatiotemporal expression pattern upon a 
linked transgene, regardless of its site of integration in the genome. These properties are 
well suited to direction of high-level, physiological expression of therapeutic antigen 
receptor genes to the T cell progeny of vector-transduced stem cells. The endogenous 
LCR spans over 12.5-kb of DNA. To accommodate LCR activity within the space 
constraints of gene delivery vectors, we aim to reduce the size of the LCR, while 
retaining its characteristics. Mini-LCRs have been constructed with varying combinations 
of previously characterized sub-elements of the TCRα LCR, ranging in size from 1.3- to 
4.0-kb. These mini LCRs are tested in an in vitro mouse embryonic stem (ES) cell 
differentiation system for their ability to recapitulate hallmark LCR properties. In T cells 
derived from ES cells, reporter gene expression driven by TαLCR4.0 approximates that 
observed in the presence of the full length LCR, in that TCRα LCR-linked reporter gene 
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expression levels are robust, mostly cell type-restricted and are upregulated during the 
expected stage transition of T cell development. Reporter gene expression driven by a 
smaller mini LCR, TαLCR1.3, while robust in all clones, displays early activation 
kinetics suitable for directing therapeutic gene expression to correct inherited 
immunodeficiency. TαLCR2.9 and TαLCR3.0 drive tighter spatiotemporal expression by 
restoring deleted elements from TαLCR1.3, and two other mini LCR cassettes have been 
designed to further narrow down the sub-elements conferring function. This 
structure/function information contributes to characterization of the elements of TCRα 
LCR, and can enable a better understanding of the basic scientific mechanisms 
underlying the gene regulation in the TCRα locus. Furthermore, incorporating TCRα-
derived mini LCRs into gene delivery vectors may provide the controlled and predictable 
therapeutic gene expression required to overcome some of the current hurdles to the use 
of genetically engineered stem cells as vehicles for delivering T cell gene therapy against 
cancer and a variety of other diseases.	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Chapter 1. Introduction  
1.1 Genomic landscape and regulation              
 
The complex and dynamic nature of the eukaryotic genome necessitates the juxtaposition of 
genes with disparate functions in space and time on the chromosome. This seemingly random 
landscape therefore requires high-level regulation yielding appropriate gene expression patterns.  
As such, there exist cis-acting DNA elements that act as molecular switches, turning genes on 
and off in a predictable and specific manner.  Many of these elements function by directly 
altering the activity of RNA polymerase thereby influencing the production of transcript. Such 
elements include promoters and enhancers, which can bind to transcription factor complexes and 
in turn modulate RNA polymerase binding. Others, such as insulator elements, or trans-acting 
factors like histone or DNA modifying enzymes1, can enable epigenetic modifications to the 
DNA2, 3, affecting the accessibility of the chromatin to RNA polymerase and its associated 
factors. Chromatin accessibility is dictated largely by the way it is wrapped around histone 
proteins4. In its heterochromatin state, DNA is tightly bound to histones, making it difficult to be 
transcribed. In contrast, euchromatin is more loosely packed, permitting the binding of 
transcription machinery and thus gene expression. Both states are associated with various 
modifications made to the DNA or histones- these marks can facilitate differential affinities for 
the histones, based on electrostatic charges, and inter-nucleosomal interactions5.  
 
Gene regulation can also be mediated via long-range chromatin interactions that can render 
entire gene loci either permissive or non-permissive for transcription6. These interactions are 
largely responsible for the 3D genome architecture and formation of chromatin hubs. When 
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distal regions of DNA are brought into close proximity via protein-protein interactions, gene 
expression can be positively or negatively influenced. DNA looping can bring entire 
chromosomal regions to the nuclear periphery, rendering them non-amenable to transcription6. 
Alternatively, looping can poise a gene for transcription by enabling the formation of 
transcription complexes at a particular locus by bringing distal elements, such as promoters and 
enhancers, into closer proximity6.7 Higher-order chromatin structure can be understood at the 
level of topologically associated domains (TADs), which describes the broader chromosomal 
interactions that are associated with active or inactive domains8. The boundaries of TADs may 
be associated with insulator-like elements that can establish barriers between neighboring 
regions9.  
 
The complexity underscoring the dynamic nature of eukaryotic gene expression necessitates 
regulation at the local genomic region as well as the higher-order, three-dimensional structure. 
The integration of these instructions allows for proper expression of genes in space and time. It is 
therefore of great importance to understand the underlying mechanisms of gene regulation, given 
its role in development and homeostasis.   
 
1.2 Locus Control Regions 
 
Oftentimes, it is the synergistic effects of multiple regulatory elements that are responsible for 
the overall patterning of a particular gene’s expression. There exist elements, however, that can 
encompass the properties of multiple regulatory regions.  One such element, the Locus Control 
Region (LCR), acts to confer multi-layered regulation upon a linked gene10. LCRs are 
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conglomerates of DNase hypersensitive sites (HS) that can be identified and characterized 
individually. Together, however, the sites can enhance and drive regulation of a linked gene in a 
pattern that is reflective of its locus of origin10, 11, 12, 13. Within the scope of an LCR lies the 
ability to drive copy number dependent, spatiotemporally specific expression of a linked 
heterologous gene, regardless of its genomic integration site14. These functions are mediated by 
multiple transcription factors that bind at various regions of the LCR. 
 
The first LCR was discovered in the human β-globin locus14. Patients afflicted with γβ 
Thalassemia had intact β-globin genes, but suffered from deletions in regions upstream15. This 
moved scientists to extend their search beyond the coding region of the locus, and further 
upstream into non-coding regions. It was there that they discovered five HS that collectively 
supported the spatiotemporal gene expression pattern of the locus14. These regions impacted 
hematopoiesis from as early as fetal development. Human hematopoiesis occurs with the step-
wise activation of five genes within the globin locus (ε, Gγ, Aγ, β, and δ), which are responsible 
for the generation of functional hemoglobin, which carries oxygen on red blood cells. Each gene 
is responsible for the expression of globin at the various sites of hematopoiesis, beginning with 
the yolk sac (ε), transitioning to fetal liver (Gγ, Aγ), and ultimately occurring in the bone marrow 
in mature humans (β or δ). The switching of the activation of these genes, and thus the proper 
expression of globin, is mediated by the upstream HS16. Deletion of portions of these sites results 
in low-level, inconsistent gene expression, which can be rescued by inclusion of deleted gene 
fragments, indicating the importance of proper globin gene regulation in the processes of 
development and hematopoiesis. Characterization and analyses of these HS yielded what are 
now known as the hallmarks of LCR activity; the ability to promote predictable gene expression 
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that mimics the tissue restriction, and developmentally-timed patterns of the endogenously-
linked gene irrespective of the position of integration of the transgene in the chromatin. 
Additionally, the mRNA expression level of a gene linked to the LCR will be linearly correlated 
with number of genomic transgene integrants.  
 
Since the discovery of the β-globin LCR, other LCRs have been identified and studied 
(including, but not limited to, human CD217, human HLA-B718, human growth hormone19, and 
mouse T cell receptor α [TCRα])20.  These LCRs have classically been studied using transgenic 
mouse models that allow for analysis during the development of the animal. More recently, an 
embryonic stem cell differentiation model was introduced to enable a more cost effective, less 
protracted experimental setup21.  This system mimics mouse hematopoiesis in vitro over the 
course of 21 days, and allows for the generation and assay of lineages of hematopoietic origin 
such as erythrocytes, monocytes, and T cells21, 22. It allows the cis elements under study to 
experience the developmental cues and priming that might be essential for their function. The 
system is amenable to testing varying LCR constructs, and is not reliant upon the generation of 
transgenic mouse lines.  
 
1.3 TCRα LCR and its genomic locus 
 
There exists an LCR in the TCRα-Dad1 locus on mouse chromosome 1420 (Figure 1).  TCRα and 
Dad1 have unique expression patterns and different functions depending on space and time23. 
TCRα is a subunit of the αβ T cell receptor complex that mediates T cell interaction with major 
histocompatibility complex (MHC)-bound antigen on cells, making TCRα largely responsible for 
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the functional maturation of T cells as well as initiating the immune response. Endogenously, it 
is upregulated at a late stage of T cell development. Dad1, on the other hand, is ubiquitously 
expressed, at an earlier time point in development. It is known to be involved in N-linked 
glycosylation as well as preventing apoptosis24, 25. Given the two disparate functions and 
expression patterns of these neighboring genes, it was hypothesized that there must exist an 
element that can separate the observed spatiotemporal specificities. The DNA that occupies the 
genomic territory in between these two genes is a compilation of cis regulatory elements that 
have been identified by their hypersensitivity to DNase I. Together, these HS can work to yield 
proper TCRα regulation, and to maintain the differential expression patterns of TCRα and Dad1.  
 
 
Figure 1. TCRα-Dad1 genomic locus.  
DNase HS of the TCRα LCR indicated by vertical arrows. Eα, the classical enhancer is depicted 
by the dark grey box. Solid blue boxes represent the exons of TCRα and Dad1. Horizontal 
arrows indicate transcriptional directionality of gene.  
 
TCRα LCR is composed of nine DNase I Hypersensitive sites20, 23. Structure-function analyses of 
these HS have thus far revealed four HS that are essential for full LCR activity, namely HS1, 
HS1’, HS4 and HS626, 27, 28. The 5’ HS (HS1, HS1’) confer the spatiotemporal specificity as well 
as copy number dependent aspects of LCR activity, while the farther 3’ HS (HS4, HS6) maintain 
the chromatin-opening capabilities of the LCR. HS2, HS3 and HS5 have not yet been shown to 
possess any specific functions. HS7 and HS8 are proposed to be silencers 26, 29, but thus far 
appear to be dispensable for complete LCR activity, in vivo26. Establishing LCR cassettes that 
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could harness the properties of the essential HS to drive high level, predictable, and specific 
expression of a transgene could be relevant in the gene therapy space to mitigate some of the 
risks of the current treatments.  
1.4 Translating LCRs for use in gene therapy  
 
LCRs have been exploited in the field of gene therapy in order to drive predictable therapeutic 
gene expression from viral vectors30. Viral vectors bearing components of the β-globin LCR 
have demonstrated varying levels of success, where they have been shown to restore β -globin 
levels in thalassemic mice30. The β-globin levels achieved in mouse studies, however, were 
insufficient for human treatment, and thus larger subregions of HS, as well as the chicken HS4 
insulators were added to boost response31, 32, 33. Attempts to test regulatory sub-components of 
other LCRs (hADA, hCD2) for therapeutic purposes have also been made, and can drive 
position-independent, tissue-specific expression in vitro34, 35, 36, but have yielded limited effects 
in in vivo models, with limited transgene expression which was not copy-number dependent37 .  
Other applications of gene therapy, currently use more constitutively active regulatory elements 
to drive gene expression. Of particular interest is immunotherapy, wherein the patient’s immune 
system is harnessed to fight against certain diseases.   
 
In particular, engineered T cells that recognize specific antigens are now being used in humans to 
fight forms of cancer and other conditions38, 39. Chimeric Antigen Receptors (CARs) are 
designed to bind to cell surface proteins on subsets of patients’ cells and initiate an immune 
response that will eradicate them. For the purpose of gene therapy, CAR transcription units can 
be introduced into a patient’s T cells ex vivo, after which the CAR-expressing cells can be 
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infused into the patient.  It is important to introduce these CAR transcription units only into T 
cells, however, because they are widely active, and could be expressed in many cell lineages 
other than T cells, and at all times. This could result in the targeting of inappropriate cell types to 
tumor cells. Additionally, CAR-driven genes might be subject to position effects at their site of 
integration in the genome, as vectors are un-insulated. This might cause vector silencing, and 
unpredictable longevity of CAR+ T cells in transplant recipient.  Indeed, this issue is already 
manifested in the highly variable data on the persistence of CAR+ T cells in a patient40. The 
longevity of the treatment is often associated with T cell persistence or exhaustion. Even if the T 
cells remain in circulation, however, there is a possibility that they will not express the 
engineered therapeutic gene if it is integrated into an inaccessible DNA region or due to 
epigenetic silencing. The ability of the TCRα LCR to dictate the predictable, spatiotemporally 
restricted expression of a T-cell receptor seems tailor-made for the purpose of targeting the 
expression of a chimeric receptor, given the T-cell receptor’s role in mediating the immune 
response against selected antigens. As such, linking the TCRα LCR to a CAR, or another 
therapeutic gene, can add a layer of regulation and specificity to the T cell gene therapy platform, 
which can improve safety and efficacy of the therapeutic model. It is known that expression of a 
TCR in the incorrect cell type, or at an early stage of T cell development can be deleterious, and 
can even lead to malignancies41, 42.  Accordingly, the TCRα LCR can drive T cell specific 
expression of a linked gene to mature T cell populations, which can address this concern. In 
addition, TCRα LCR’s ability to modulate gene expression that is resistant silencing can improve 
the efficacy and duration of response in this model.   
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Therapeutic gene delivery, in the context of CARs, is administered via patient T cells, which can 
recognize and target desired cell populations for elimination. Peripheral Blood Mononuclear 
cells (PMBCs), from which T cells can be derived, are isolated from the patient. These T cells 
can then be transduced with viruses (such as lentivirus) containing the therapeutic gene of 
choice, and expanded ex vivo before being re-infused into patients. Transduced T cells, when put 
back into patients, have been very successful in clearing blood cell tumors43, 44 (Figure 2).  
 
 
Figure 2. T cell transfer for CAR immunotherapy.  
T cells are derived from patient blood, and engineered to express a particular Chimeric Antigen 
Receptor (CAR). CAR-expressing cells are selected and expanded, after which they can be 
infused back into the patient. (Adapted from 45) 
 
 
9	  	  
There is varying data, however, as to how long these “therapeutic T cells” will remain in 
circulation, ranging from months to up to 4 years, depending on the trial and tumor type 
(reviewed in 40). If circulating T cells do not persist for a long enough period to fully clear a 
tumor, patients might require reinfusion with a new pool of cells, which is labor intensive, and 
costly. Alternatively, therapeutic cells that circulate beyond tumor clearance might result in 
depletion of off-target cells, inducing negative side effects. In order to provide a renewable 
source of engineered T cells, it might be advantageous to transduce a stem cell population that 
will remain present for the duration of the patient’s lifetime. Insertion of therapeutic genes into 
these populations, however, may result in the expression of the gene in all the progeny of the 
stem cell source, potentially directing of all cells derived from the source to the selected target, 
which might be deleterious in the clinic. Alternatively, when randomly integrated into the 
genome, therapeutic genes might be silenced over time, thereby eliminating their clinical impact. 
It is therefore essential to reconcile the need for long-term therapy with targeted, predictable 
expression to specific cell lineages. Utilizing the properties of TCRα	  LCR seems to remedy some 
of the current limitations associated with existing therapeutic models: therapeutic gene-bearing 
vectors including TCRα LCR-derived elements can be used to transduce HSCs, as they should 
produce cargo gene expression that mimics cell type- and developmental timing-specificity of 
the TCRα. Namely, only T cells that emerge from transduced HSCs will express the therapeutic 
gene at the proper stage of T cell maturation. Additionally, the LCR will introduce yet another 
layer of protection to the linked therapeutic gene; it will enable expression from any integration 
point within the genome, that will be resistant to chromatin-induced silencing, which can impact 
the durability and efficacy of the response.  
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CARs, or other therapeutic genes must be introduced to a patient’s cells in safe and efficient 
ways. While there exist various gene-delivery vehicles, viral vectors are a popular way to 
introduce genes into cells. In particular, lentiviral vectors have been useful for their ability to 
stably integrate into the genome of non-dividing cell populations, such as hematopoietic stem 
cells.  Lentiviral vectors, however, can hold up to approximately 8kb of exogenous DNA without 
compromising packaging ability46. Beyond this DNA limitation, the efficiency of the virus to be 
assembled is significantly lessened. This 8kb limit is exceeded by that of the TCRα LCR, as it 
spans 12.5kb in the genome20. Therefore, in order to make this gene regulatory element 
amenable for use in these vectors, it is necessary to reduce it in size, while retaining its ability to 
drive predictable gene expression patterns. To accommodate this limitation, only the portions of 
the TCRα LCR that have been shown to have functional importance have been included within 
‘mini LCR’ constructions, which can be incorporated into lentiviral vectors. The largest of the 
mini LCRs, made by Dr. Armin Lahiji, includes the four HS regions (HS1, HS1’, HS4, HS6) that 
have been demonstrated to contribute to the spatiotemporal specificity, and/or chromatin opening 
functions of the LCR in transgenic mouse models26, 27, 28, 47. This mini-LCR is only 4kb, which 
represents a reduction of over 70% of the full-length 12.5kb TCRα LCR, and is small enough to 
be incorporated into a lentiviral vector. Other variations of these mini-LCRs include further 
reduced sub regions of the required HS. These mini LCRs can be tested for their ability to 
recapitulate full LCR activity, and drive reporter gene expression with expected TCRα-like 
patterning, through development in an in vitro differentiation system, and when transduced into a 
stem cell population.  
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This study, therefore, addresses both basic and translational applications of the regulatory 
function TCRα LCR, enabling a two-pronged approach in addressing biological questions and 
applying the resulting knowledge for tangible solutions. Firstly, we aim to minimize the LCR 
DNA without compromising classical LCR properties. Various permutations and deletions of 
HS, or portions of HS, will be combined into ‘mini LCRs’, which can be assessed for their 
ability to recapitulate full LCR activity. This aspect of the project will elucidate which TCRα 
LCR components are necessary and sufficient, and can help us begin to understand the possible 
interplay between them. In addition to this contribution to basic science, these mini LCRs might 
be clinically relevant for use in gene therapy. We explore their potential to be incorporated into 
lentiviral vectors, in order to regulate a linked therapeutic gene in a TCRα-like pattern. In this 
way, we achieve a better understanding of the underlying regulatory mechanism of the TCRα 
LCR, while also aiming to make it translationally applicable. 
 
Chapter 2. From stem cells to T cells  
2.1 ESCs 
 
Embryonic stem cells (ESCs) are derived from the inner cell mass (E3.5) and are characterized 
by their pluripotency and ability to self-renew48, 49. These cells can give rise to all three germ 
layers in a developing embryo in vivo. In vitro, ESCs can be maintained in their pluripotent state 
by culturing them on a feeder matrix and with the addition of leukemia inhibitory factor (LIF)50. 
Removal of these conditions results in the spontaneous differentiation of the cells into embryoid 
bodies, three-dimensional aggregates of ESCs that possess the potential to contribute to a 
heterogeneous cell population, including blood mesoderm precursors, endoderm, and 
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hematopoietic lineages51. The microenvironment and the factors52 within it contribute to the 
determination of lineage choice. These circumstances can be manipulated in vitro in order to 
derive particular cell types.  
 
2.2 Hematopoiesis  
 
Hematopoietic precursors also have the ability to self-renew in their multipotent state, as well as 
give rise to all blood lineages. Hematopoietic development in the mouse begins at E7.5 in the 
yolk sac, which is the site of primitive hematopoiesis. This stage occurs only early in 
development, and is typically restricted as to the types of blood cells (generally red blood cells 
and macrophages) that emerge. The transition to the aorta-gonad-mesonephros (AGM) region 
marks the switch to definitive hematopoiesis, around E10.5 where the first emergence of 
hematopoietic stem cells (HSCs) occurs53, 54. These HSCs seed the fetal liver, and ultimately the 
bone marrow, where the hematopoietic niche is established and maintained throughout 
development.  The bone marrow niche is supported by cellular constituents (such as 
osteoblasts55), as well as other factors such as cytokines and chemokines (which drive 
differentiation to specific cell-types)56, 57, protein factors, as well as oxygen and calcium levels58, 
59. Together, these components provide the micro-environment that is necessary for 
differentiation of blood lineages60.  
 
Within the bone marrow, HSC pools are maintained via self-renewal, or are able to differentiate 
depending on environmental cell fate determination. HSCs are mostly quiescent, and divide 
rarely in order to regenerate the stem cell pool61.  Bone marrow HSCs can further differentiate 
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into multipotent progenitors (MPPs), which give rise to the common myeloid progenitors 
(CMPs) and common lymphoid progenitors (CLPs). CMPs, upon subsequent development, can 
yield myeloblasts (including monocytes), mast cells, megakaryocytes, and erythrocytes. CLPs, 
on the other hand, give rise to natural killer, dendritic, B and T cells. Niche conditions as well as 
the factors available within are largely responsible for the hematopoietic fate of these cells. 
Many hematopoietic lineages can be derived from ESCs in vitro by mimicking the signals 
experienced in vivo through development62.   
 
2.3 T cell development 
 
A small subset of CLPs is able to migrate and settle in the thymus, a process supported by the 
expression of particular cytokines, and chemokine receptors. Progenitors expressing fms-like 
tyrosine receptor-3 (Flt3) at high levels are better suited for migration out of the bone marrow 
into the thymus63. The expression and signaling of Flt3 in these precursors promotes chemokine 
receptors CCR9 and CCR7 production, both of which are essential for thymic homing and 
settling64, 65. Early settlers of the thymus retain the potential to generate other alternative lineages 
(namely, myeloid, natural killer, but not B cells), which is lost over time, a process likely 
supported by the thymic microenvironment66.  
 
The Notch signaling pathway has been identified as a strong inhibitor of non-T cell lineages 
within the thymus67, 68, and is known to be responsible for many cellular bifurcation decisions68, 
69, 70, 71. There exist four Notch receptors, as well as two families of Notch ligands, Delta-like 
(DL) and Jagged.  Upon ligand binding, the intracellular domain of the receptor is cleaved and 
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enters the nucleus, binding to transcription factors to alter gene expression. During T cell 
development, Notch 1 is the receptor that is both necessary and sufficient to drive 
differentiation67, 68. When this receptor is bound by its ligand in CLPs, genes that positively 
influence T cell programs are upregulated, while the B cell program is strongly repressed.  
 
The development of the two major types of T cells, αβ and γδ, is supported by the 
microenvironment of the thymus. The framework of this niche, which includes cell-cell 
interactions, signaling, and presence of specific factors, is responsible for the differentiation, 
commitment, and maturation of these cells. The maturation of developing T cells is dependent 
upon the expression of TCR, CD4 or CD8, which are essential for interaction with self-major 
histocompatibility complex (MHC) proteins. This interaction and engagement of the TCR with 
MHC dictates the subsequent positive and negative selection processes through the development 
and functional maturation of these cells.  
 
2.4 Doing it in a dish: ESC to T cell differentiation in vitro 
 
The ability to mimic the hematopoietic niche has been harnessed to drive the differentiation of 
stem cells into multiple hematopoietic lineages, such as erythroid, monocytic, and B cells62. 
More recently, a cell culture system to derive T cells from stem cells was developed, enabling 
the study of their development in vitro22 (Figure 3). This system exploits Notch signaling to 
recapitulate the thymic environment in which T cells become committed22, 72.  
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Figure 3. OP9-DL1 system for in vitro differentiation.  
Transfected ESCs are seeded onto OP9 cells. As the co-culture progresses, Flt-3L and IL-7 are 
added to promote hematopoietic cell and lymphoid cell differentiation, respectively. Cells can 
continue to grow on OP9 (GFP) cells for erythroid and monocytic lineage generation, or can be 
transferred onto OP9-DL1 cells in order to promote T cell differentiation. Cells may be analyzed 
for reporter gene expression at various time points via flow cytometry using indicated markers to 
identify cell populations.  
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ESCs are co-cultured with a bone marrow derived cell line (OP9-GFP), providing the signaling 
to initiate the hematopoietic program22, 73. These cells are macrophage colony-stimulating factor 
(MCSF)- deficient, such that the generation of macrophages is not favored at the expense of 
other hematopoietic lineages62, 74. OP9 cells endogenously express the Jagged ligand for the 
Notch receptor, which alone is insufficient for derivation of T cells. Therefore, OP9 cells were 
retrovirally transduced with the Delta-like 1 ligand to yield the OP9-DL1 cell line upon which T 
cells can be generated22, 73, 75. 
 
Upon removal of LIF, ESCs begin to form blood-mesoderm-like colonies, which can in turn give 
rise to hematopoietic progenitor cells, when cultured on the bone marrow stromal cell line. The 
addition of Flt3L and IL7 support the development of T cells on OP9-DL1 monolayers, and other 
blood lineages with continued culturing on OP9-GFP cells (protocol outlined in 76).  The 
emerging cells can be identified by the markers on their cell surfaces. For example, cells can be 
distinguished by their absence or presence of CD45, as well as expression of Ter119 
(erythrocytes) or CD11b (monocytes). T cells undergo a sequential acquisition or loss of 
particular cell surface markers that are indicative of their stage of maturation. T cells initially 
undergo four “double negative (DN)” stages, when they are negative for both CD4 and CD8. The 
four stages can be further subdivided by the differential expression of CD44 and CD25. T cells 
then progress to the “double positive (DP)” stage, at which both CD4 and CD8 are expressed. 
Loss of either CD4 or CD8 renders the T cells “single positive (SP)” for CD4 (helper T cells) or 
CD8 (cytotoxic T cells).  This system only yields CD8 SP cells because of the lack of MHCII 
expression on OP9 cells, which is required for CD4+ T cell generation. Reporter gene expression 
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can be tracked throughout development via flow cytometry, and analyzed for adherence to 
hallmark LCR properties.   
 
Chapter 3. Characterizing TCRα LCR using in vitro ESC differentiation  
3.1 TCRα LCR HS composition and function 	  
 
Figure 4. Functional hypersensitive sites of the TCRα LCR.  
Schematic representation of TCRα LCR, where colored boxes indicate the DNase HS that have 
been functionally characterized. HS1, or Eα is the classical enhancer of the LCR. Along with 
HS1’, it confers the spatiotemporal restriction associated with LCR activity. The dotted box 
within HS1’ represents DNA 3’ to CTCF sites that is not included in a subset of mini LCR 
constructs. HS4 and HS6 are responsible for suppression of position effects. Dotted lines within 
HS6 represent functional regions TF123 and HS316. In a subset of mini LCR constructs, only 
sub regions TF123 and HS316 are included.  
 
Within the TCRα-Dad1 locus, which resides on mouse chromosome 14, there exist a 
conglomerate of cis regulatory elements that comprise the T-cell Receptor α Locus Control 
Region20. The TCRα LCR is composed of nine DNase I hypersensitive sites (HS1-8), some of 
which have been functionally characterized. The 5’ region, composed of HS1 and HS1’, is 
responsible for the spatiotemporal control as well as copy-number dependent qualities associated 
with the LCR26, 29, 77. Farther 3’ sites, HS4 and HS6 are thought to confer the position 
independence of the LCR-linked transgene27, 28, 47, 78 (Figure 4). The hallmarks of LCR properties 
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are seemingly maintained within these HS, however, it has thus far not been shown if only HS1, 
HS1’, HS4, and HS6 alone can sufficiently confer position-independent, spatiotemporally-
controlled expression patterns on transgenes.  
 
HS1, or Eα, contains the classical enhancer activity associated with the LCR29. Along with HS1’, 
HS1 yields the temporospatial control associated with LCR activity26. Within HS1’ exist two 
CTCF binding sites, which are not required for LCR activity28. CTCF, however, is a protein that 
has been widely studied and implicated for its role in establishing histone modifications79, as 
well as establishing loops and inter-domain boundaries in the larger-scale DNA architecture80, 81. 
Moreover, if bound to an insulator element, it can establish an active boundary between 
enhancers and promoters, thus establishing barriers between neighboring genes79, 80.  
 
Further 3’, HS4-region DNA has been shown to be essential for LCR activity and is selectively 
demethylated in lymphoid organs47. DNA methylation is often correlated with a closed 
chromatin structure that is inaccessible to transcription factors82, whereas a hypo-methylated 
region can be more readily available. Its differential methylation status suggests that it renders 
chromatin selectively accessible to transcription factors and other transcription machinery 
throughout various cell lineages. Notably, the establishment of this tissue-dependent methylation 
is dependent on the presence of HS1’47. Deletion of HS4 reduces LCR activity, and can render a 
gene subject to position effects, as measured by transgene expression28.  
 
Position effects refer to the impact of the genomic surroundings upon the expression of an 
integrated transgene. If integrated into a non-permissive region, gene expression can be 
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silenced48, however if a gene inserts within an accessible region, it might be expressed, and 
potentially influenced by the neighboring elements83. Therefore, the site of genomic integration 
can dictate whether or not a gene will be expressed or silenced. HS6 alone has the ability to 
overcome position effects, and plays a role in preventing the encroachment of silencing 
heterochromatin upon a transgene27, 78. Specifically, there are two sub-regions within HS6 that 
are required for this activity. TF (Thymic Footprint)-1-2-3 is a region that consists of three 
factor-binding sites, each of which binds to factors involved in chromatin remodeling78. TF2 
binds to AML/Runx1 proteins, while TF3 binds Elf1, a member of the Ets protein family27. In 
addition to the three thymic footprint regions, there is a 316-bp region that is required for high-
level transgene expression in mice. Deletion of the TF123 or the 316-bp region within HS6 
results in significantly reduced transgene expression, likely owing to the inability of the LCR to 
properly regulate expression-favoring chromatin conformations27.  In the absence of HS1’, 
however, the activity of the LCR-linked transgene becomes widespread27. HS7 and HS8 contain 
silencer region20, and are dispensable for LCR activity77. Thus far, the function (if any) of the HS 
2,3, and 5 regions has not been determined.  
 
Because the LCR is able to exert its functions upon a linked transgene in the TCRα position, it 
can be utilized to drive reporter gene expression with a TCRα-like spatiotemporal pattern. While 
it is known that HS1, HS1’, HS4, and HS6 contain the properties associated with hallmark LCR 
functions, it is heretofore unknown whether these HS alone can provide such regulation in 
combination with one another. Furthermore, testing of different combinations of these sites, 
along with sub-HS deletions thereof, can add to the understanding of how each element 
contributes to overall LCR capabilities, including potential redundancies, and synergies.  The 
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application of the data acquired from TCRα LCR studies can allow for the generation of mini 
LCRs containing only a subset of varying characterized HS. Studies can yield information on the 
basic structure-function of LCR elements, as well as utility in a translational approach, where the 
LCR can be linked to a heterologous therapeutic gene in an immunotherapy setting.  
 
3.2 Honey, I shrunk the LCR: generation of mini-LCRs 
 
The endogenous TCRα LCR spans over 12.5kb in genome20. The sites lying within this range 
together, and potentially with the help of other elements, can drive the gene expression pattern of 
the neighboring TCR gene. Structure/function data describing the activity of particular HS were 
utilized in the construction of various mini LCR cassettes. Each mini LCR will consist of various 
HS (and sub-HS), and are designed to test if particular HS are sufficient to reproduce full LCR 
activity. These constructs will further test and dissect HS1’, HS4, and HS6 regions for their 
ability to work in concert and in assorted arrangements. Dissection of HS guided by years of 
characterization to further reduce the known functional regions, can pinpoint activity to a 
narrower sequence.  Deletion, or inclusion of only conserved regions within other HS can yield 
interesting knowledge on its relevance, or potential redundancy and possible interactions within 
the LCR. Mixing and matching these altered HS can provide significant data and insight into the 
inner-workings of the LCR. Not only can we use these cassettes to identify necessary and 
sufficient HS, but once mini LCRs are generated that can amply recapitulate full LCR activity, 
they will be within the size confines for incorporation into viral gene therapy vectors for use in 
the treatment of genetic insufficiencies and diseases. Gene therapy vectors are capable of holding 
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only limited amounts of exogenous DNA, so condensing the LCR would be essential for 
packaging and utility in a therapeutic model.  
 
Figure 5. Mini LCR constructs.  
Constructs were generated and incorporate varying combinations of HS1, HS1’, HS4, HS6, and 
sub-regions within these HS. All cassettes include the HS1 core enhancer region. In addition to 
HS1, TαLCR4.0 includes the full HS1’, HS4, and HS6. TαLCR3.0 and TαLCR2.9 include the 
full HS1’, and HS6, but the former includes an HS4 homology block, while in the latter, HS4 is 
not included at all. A sub-element of HS1’ that includes all DNA until the CTCF site is utilized 
in TαLCR2.6 and TαLCR1.3. Only TF123 and HS316 regions of HS6 are utilized in TαLCR1.6 
and TαLCR1.3. Mini LCR constructs are linked to a hCD2 reporter gene driven by the hCD2 
promoter. 
 
 
In accordance with the aforementioned objectives, five mini-LCR cassettes were generated and 
assayed for their ability to retain hallmark LCR properties (Figure 5). These constructs were 
designed with varying HS incorporations that would help identify functional information about 
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the LCR components. The largest of the mini-LCRs, TαLCR4.0 is 4kb in length and includes 
HS1, HS1’, HS4, and HS6. (Lahiji, thesis 2013). The smallest of the mini-LCRs is 1.3kb long, 
containing only sub-elements residing in HS1, HS1’, and HS6, shrinking the size of the LCR by 
nearly 80% (Lahiji, thesis 2013).  These sub-elements were chosen based on structure-function 
studies done previously in the lab. They include all DNA of HS1’ 5’ of the two CTCF sites 
(including both the canonical and non-canonical CTCF sites), and the TF123 and HS316 regions 
of HS6. Both TαLCR4.0 and TαLCR1.3 were designed and constructed by Dr. Armin Lahiji. HS 
and their sub-regions were assembled in varying combinations in order to test individual regions 
for their ability to contribute to LCR activity. In one, TαLCR2.9, DNA 5’ of the CTCF site in 
HS1’ as well as all excluded DNA from HS6 was included to yield a construct containing a full 
HS1, HS1’, and HS6. This construct tests whether HS4 is necessary for providing predicted 
TCRα-like expression patterns. Based on bioinformatics analyses of homology between the 
murine and the human TCRα LCR sequences, a mini LCR (TαLCR3.0) was generated that 
contains the complete HS1, 1’, and 6 regions along with the homology block of HS4 (Valia 
Kostyuk). This was made based on the hypothesis the homology regions would be conserved 
based on their importance in retention of HS4 function (Figure 11, page 33). Yet another 
cassette, TαLCR1.6, was built to test whether the end of HS1’ contained the activity necessary 
for full LCR function. This contains the full HS1, HS1’ and only the TF123 and HS316 regions 
of HS6. If, indeed, LCR-conferred properties are exhibited by reporter gene driven by 
TaLCR1.6, it demonstrates importance for the 3’-most region of HS1’. Lastly, if the deleted 
regions of HS1’ failed to restore LCR activity, the function might be held within the portions of 
HS6 that lie outside of TF123 and HS316. Therefore, TαLCR2.6 was created to contain a 
restored HS6 with a reduced HS1’.  
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3.3 TαLCR4.0 	  	  
Four of the nine DNase I HS were chosen for incorporation into the largest of the mini LCRs 
based on structure/function analyses from our lab and others. ESCs were co-transfected with 
hCD2 reporter84-linked TαLCR4.0 and a neomycin resistance gene. Upon G418 selection, 
individual ESC colonies were picked and screened via PCR and Southern Blot. Positive clones 
were subject to differentiation via the OP9-DL1 system, and driven to erythrocytes, monocytes, 
and T cells. Over the course of the 21-day differentiation, hallmark spatial and temporal LCR 
properties are assessed via flow cytometry at various time points. On the final day, total RNA is 
collected, and measured via qRT-PCR to assess for copy number dependence.  
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Figure 6. TαLCR4.0 drives expression of a reporter TCRα-like spatiotemporal patterning.  
Histograms reflect hCD2 reporter gene expression in T cells, erythrocytes, or monocytes derived 
from ESC differentiation using the OP9-DL1 system. The red line represents hCD2 expression in 
an un-transfected clone run alongside clones bearing TαLCR4.0,	  which	   are	   indicated	   by	   the	  blue	   line. (A). TαLCR4.0-driven reporter is expressed in a TCRα-like manner, and is most 
robustly upregulated in DP T cells. In erythrocytic populations derived from differentiated ESCs, 
reporter expression does not exceed that observed in untransfected control. In monocytes, low-
level reporter expression is observed in a small population of cells. (B). TαLCR4.0 displays 
predicted developmental onset of reporter expression. There is no appreciable expression in early 
stage T cells, whereas significant upregulation is observed at the DN3-DP transition.  
 
 
Even in the absence of approximately 70% of LCR DNA, TαLCR4.0 appears to support the 
spatial, temporal, and copy number dependent properties of the LCR (Figures 6,7). Additionally, 
all clones expressed the transgene, indicating its ability to confer position independence. On day 
12, we analyze erythrocytes (CD45-, Ter119+), and monocytes (CD45+, CD11b+), for hCD2 
reporter gene expression (Figure 6A). FACS analyses of erythrocytic cells reveals that there is no 
hCD2 expression above the untransfected control. There is, however, a small shift in a 
population of monocytic cells that indicates ‘leaky’ LCR-driven expression. This upregulation 
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might be attributed to the absence of sequences outside HS1, HS1’, HS4, and HS6 that might 
further tighten the cell specificity associated with the complete TCRα LCR. Additionally, the 
spacing of DNA in the endogenous locus might be required for establishment of chromatin 
topology that is conducive to DNA-factor interaction, thereby facilitating expected expression 
patterns. Early stage T cells (DN1: CD45+, CD44+, CD25-, CD4-, CD8-; DN2: CD45+, CD44+, 
CD25+, CD4-, CD8-) were also analyzed for hCD2 reporter gene expression (Figure 6B). As per 
expectations, there is no significant reporter expression prior to the predicted onset of expression. 
In contrast, later stage T cell progeny DN3 (CD45+, CD44-, CD25+, CD4-, CD8-) and DP 
(CD45+, CD44-, CD25-, CD4+, CD8+) cells expressed high levels of the hCD2 reporter gene 
(Figure 6B).  All clones that were generated and tested display similar patterns to representative 
clones shown above, with the exception of a single clone, which displayed higher expression of 
the hCD2 reporter gene in monocytic populations, as well as a bimodal peak observed at later 
stages of T cell development.  Southern blot analysis indicated that this clone, however, appears 
to have incorporated truncated transgenes, and thus was excluded from the analyses. 
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Figure 7. TαLCR4.0-bearing clones drive reporter mRNA expression in a copy number 
dependent manner.  
(A). RNA was collected from day 20 of co-cultures, which mainly consist of DP and CD8 SP T 
cells, and was analyzed via qRT-PCR. To account for the heterogeneous co-culture, data were 
normalized using TCRα primers. Expression is represented as percent max per copy to account 
for difference in copy number among individual TαLCR4.0 clones, enabling cross-comparison 
between clones. Copy number is determined from averaging Phosphorimager analyses from 
three Southern Blots.  The value of the highest- expressing clone is set to 100%. mRNA 
expression falls within a narrow range of 1.6 fold difference indicating retention of copy number 
dependence. (B). Graph of the correlation between relative mRNA level and transgene copy 
number. Microsoft Excel was used to calculate x-y value correlation and (r) value (on graph). 
The p value was derived from an F test on the linear relationship between x and y values and 
p<0.05.  
 
 
Additionally, the copy number relatedness supported by the TαLCR4.0 mini LCR is equivalent 
to that of the full length TCRα LCR, with variation of mRNA levels per copy falling within a 
narrow 1.6 fold range (Figure 7). It is accepted within the field that mRNA levels falling below a 
3-fold range of variation are said to be copy number dependent, under ~10-fold partially copy 
number dependent, and above a ~10-fold difference is outside the range of copy number 
dependence85.  In order to assess for this hallmark LCR feature, RNA is collected from co-
cultures on day 20, and subject to q-RT-PCR analysis. Typically, these cultures are composed of 
mature T cells, either in the double positive, or CD8 single positive stage of development. To 
account for the heterogeneous nature of the population, data are normalized using TCRα primers. 
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In order to enable cross-comparison between clones of varying copy number, data are also 
normalized by dividing each clone by the number of integrants, as determined using Southern 
Blot analysis. This allows us to express data as percent max expression per copy (y axis). The 
percent max expression per copy of the highest expressing clone can be compared to that of the 
lowest expressing clone, and would be expected to fall within a narrow range (as indicated 
above), if the feature of copy number dependence is retained.  
 
3.4 TαLCR1.3 	  	  
In order to further reduce the size of the 4.0kb mini-LCR, deletions were made within HS1’ and 
HS6 based on previous data, and HS4 was removed to yield a 1.3kb mini-LCR. Analyses from 
flow cytometry results of erythrocytes show that there is no expression of hCD2 in these cells. In 
monocyte populations, however, there appears to be ectopic reporter gene expression, indicating 
a loss in the ability of the TαLCR 1.3 to control the cell type-restriction of the linked gene 
(Figure 8A).  
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Figure 8. TαLCR1.3 drives promiscuous transgene activity in monocytes and early-stage T cells.  
Histograms reflect hCD2 reporter gene expression in T cells, erythrocytes, or monocytes derived 
from ESC differentiation using the OP9-DL1 system. The red line represents hCD2 expression in 
an un-transfected clone run alongside clones bearing TαLCR1.3,	   which	   are	   indicated	   by	   the	  blue	   line. (A). While reporter expression is restricted within the erythrocyte lineage, ectopic 
expression is seen in monocytes derived from ESCs. (B). Early activation kinetics of reporter 
gene begins at the immature DN1 stage. Expression increases, as expected with T cell 
maturation.  
 
Additionally, there are early activation kinetics associated with this version of the mini LCR that 
suggest that the developmental timing property of the TCRα LCR is compromised (Figure 8B). 
Endogenous TCRα expression is upregulated in late-stage T cell development (DP), which is 
mimicked in the in vitro differentiation system using the full-length LCR, as well as with 
TαLCR4.0, where significant upregulation is initiated between DN3-DP late stage T cell 
development. TαLCR1.3-driven transgene expression, on the other hand, is initiated beginning at 
the early DN1 stage. Robust expression of the reporter gene is seen in more mature T cell 
populations. Further reduction of HS1’ and HS6, or loss of HS4 could potentially be responsible 
for the observed promiscuous activity. Extraction of mRNA from day 20 co-cultures, and 
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analysis via qRT-PCR showed a loss of full copy number dependence from these cultures. A 
Fold difference of 8.49 is measured, which falls within the range associated with partial copy 
number dependence (Figure 9). It might be noted, based on the data below, that clones bearing 
higher numbers of integrants have a lower percent max expression per copy relative to those of a 
lower copy number. This phenotype might be the result of multi-copy inhibition, in which the 
presence of more integrants acts to negatively impact transcription, lowering the overall 
expression per copy. While this explanation is plausible, more clones with higher copy numbers 
would be necessary for confirmation. Alternatively, the notion of multi-copy saturation, in which 
the amount of RNA is limited after a certain number of copies, might explain this observation as 
well. This can result from transcription factor or polymerase availability in the cell. While this 
observation is evident in clones bearing TαLCR1.3, the same does not necessarily hold true for 
TαLCR4.0. Therefore, some of the elements that are present in TαLCR4.0, but absent in 
TαLCR1.3 might subject the transgene to this saturation.  
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Figure 9. TαLCR1.3-bearing clones drive reporter mRNA expression in a partially copy number 
dependent manner.  
qRT-PCR analyses done on mRNA extracted from Day 20 co-cultures, normalized to TCRα, and 
for copy number, indicate an 8.49 fold difference, indicating partial copy number dependence of 
TαLCR1.3-driven reporter. (B). Graph of the correlation between relative mRNA level and 
transgene copy number. Microsoft Excel was used to calculate x-y value correlation and (r) value 
(on graph). The p value was derived from an F test on the linear relationship between x and y 
values and p<0.05. 
 
3.5 TαLCR2.9 
 
In order to determine which of the deleted elements in TαLCR1.3 was responsible for the loss of 
certain aspects of LCR activity, we restored the missing DNA in HS1’ and HS6 to the full 
hypersensitive sites, thus yielding a mini-LCR that includes HS1, HS1’, and HS6 only. The 
absence of HS4 will inform more about its relevance in providing LCR associated activity. It is 
known that deletion of HS4 in transgenic mice results in low transgene expression with altered 
tissue distribution28. Moreover, this activity is associated with its tissue-selective demethylation, 
reliant on the presence of HS1’47. It is unknown, however, in what capacity HS4 synergizes with 
other LCR elements, and the precise mechanism by which HS4 functions. Its deletion in this 
context will enable a better understanding of whether HS4 is required, and which of the other HS 
are necessary or potentially dispensable in its function.  
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Figure 10. TαLCR2.9 displays expected onset of developmental expression, and tissue 
restriction.  
(A). Analysis of two clones bearing TαLCR2.9 shows restriction of transgene expression to T 
cells, as minimal expression in seen in erythrocytes, and monocytes. (B). Reporter expression 
driven by TαLCR2.9 is not turned on until late stage T cell development, however a bimodal 
peak is observed, suggesting potential position effect variegation. 
 
Data thus far from co-culture experiments using TαLCR2.9 constructs reveal that surprisingly, 
the LCR property of spatiotemporal specificity is maintained throughout development. 
Expression is not initiated until the expected DN3-DP transition (Figure 10B), albeit in a 
bimodal fashion. This expression is mainly restricted to T cell progeny (not expressed in 
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erythrocytes or monocytes) (Figure 10A). But the bimodal expression in later stage thymocytes 
may be an indication of the transgene being subject to position effects. This is not surprising, as 
HS4 deletion experiments conducted in transgenic mice resulted in reduced transgene 
expression, indicating the HS4 regions potential role in positively influencing chromatin 
structure in T cells28.  
 
3.6 TαLCR3.0 	  	  
Bioinformatics analysis (Valia Kostyuk) identified regions of HS4 with homology to human 
sequences within this locus. Three homology blocks (blocks 296, 297, 298) with the highest 
percentage of homology (of 459 analyzed blocks) were assembled to form the “hHS4” homology 
unit, which was incorporated into TαLCR2.9 in the place of HS4 (Figure 11).  
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Figure 11. A conserved sequence within HS4 for incorporation into mini LCR cassette.  
(A). Cross-species DNA sequence analysis (including mouse/human) revealed a <200bp 
fragment of homology lying within the HS4 region. (B). This region is composed of three 
separate blocks, with the highest sequence homology (blocks 296 [20nucleotides, 65% 
homology] (red), 297 [55 nucleotides, 62.5% homology]  (blue), 298 [67 nucleotides, 60% 
homology] (green)), with 57 intervening nucleotides in between blocks 297 and 298. (C). 
Predicted protein binding sites within region of HS4 homology.   
34	  	  
  
  
Cross-species evolutionary conservation can indicate importance and potentially function of a 
sequence. Therefore, in order to minimize HS4 from 1.1kb to less than 200bp, only regions 
containing human-homologous sequence were incorporated into the mini LCR. When two ESC 
clones bearing TαLCR3.0	   were	   differentiated,	   monocytes	   and	   erythrocytes	   from	   the	  emerging	   cultures	   were	   negative	   for	   reporter	   gene	   expression	   (Figure	   12A).	   Expression	  was	  not	   activated	   in	  DN1	  T	   cell	   populations,	  however	   in	   later	   stage	  pools,	   robust,	   rather	  than	   bimodal,	   expression	   was	   observed	   (Figure	   12B).	   It	   should	   be	   noted	   that	   these	  preliminary	   studies	   do	   not	   include	   data	   from	   DN2	   and	   DN3,	   which	   would	   give	   a	   more	  complete	   understanding	   regarding	   the	   developmental	   onset	   of	   expression	   of	   hCD2.	  
Figure 12. TαLCR3.0 
incorporates a homology 
block residing in HS4 that 
restores tissue specificity and 
maintains later stage 
activation.  
(A). Reporter expression 
driven by TαLCR3.0 is 
restricted to T cell progeny of 
differentiated ESCs. (B). At 
early stage DN1, there is no 
transgene expression, whereas 
in more mature T cell 
populations, there is robust 
upregulation. DN4+ cells are 
gated on CD25-, CD44-.   
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However,	   these	   studies	   generate	   a	  broad	  picture	  of	  hCD2	  expression	   in	   immature	   (DN1)	  versus	   more	   mature	   (DP)	   T	   cell	   populations.	   These	   preliminary	   data	   suggest	   that	  incorporation	  of	  just	  a	  small	  region	  of	  mouse-­‐human	  homology	  in	  HS4	  of	  the	  TCRα	  LCR	  can	  restore	   some	   of	   the	   activity	   lost	   upon	   deletion	   of	   the	   entire	   HS4,	   namely	   the	  reestablishment	  of	  robust	  transgene	  expression	  in	  mature	  T	  cell	  stages.	  This	  might	  be	  the	  result	   of	   predicted	   factor	   binding	   sites,	   which	   can	   harbor	   the	   proteins	   that	   can	   be	  implicated	  in	  chromatin	  modulation	  and	  T	  cell	  development.	  For	  example,	  members	  of	  the	  RUNT	  and	  ETS	  protein	  families,	  among	  others,	  have	  been	  shown	  to	  have	  a	  role	  in	  histone	  interactions86,	   87	   and	   nucleosomal	   positioning88,	   which	   can	   directly	   impact	   the	   local	  chromatin	   structure.	   Thus,	   this	   block	   of	   homology,	   containing	   predicted	   protein	   binding	  sequences,	   represents	   a	   narrower	   region	   in	   which	   the	   function	   of	   HS4	   can	   potentially	  reside.	  	  	  
3.7 Rescuing lost aspects of LCR activity: TαLCR1.6 and TαLCR2.6 
 
An element potentially required for the restoration of lost activity seen in TαLCR1.3 is ~300bp 
region 3’ to the CTCF sites in HS1’. Despite the fact that the activity of the LCR is CTCF-
independent28,  these sites were included in the mini-HS1’ used in the construction of mini LCRs 
given the known importance of CTCF in gene regulation. Further 3’ DNA was omitted in an 
effort to reduce LCR size, and to further constrain the HS defined by restriction mapping26.  
HS1’ forms strongly in both lymphoid and non-lymphoid tissue, and is involved in the formation 
of differential chromatin structure in HS4 and HS626. It is possibly through the control of the 
local LCR chromatin landscape that it mediates the lymphoid-specific nature of TCRα. With this 
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in mind, the 3’ region of HS1’ was reincorporated into TαLCR1.3 in hopes of restoring greater 
cell type-specific function to the mini LCR.  
 
The final factor that distinguishes the TαLCR1.3 from TαLCR4.0 is the full HS6. A construct 
was designed to include the sub-region of HS1’ containing DNA up to the 3’ CTCF site, with 
HS6 in its entirety was also generated for future testing. If LCR activity is not rescued by the 
addition of the full HS1’ region, perhaps it is retained within HS6 sub-regions outside of TF123 
or HS316. 
 
The above constructs have been designed, cloned, and transfected into ESC for future 
differentiation and analyses.  
 
Chapter 4. Translating TCRα LCR for use in gene therapy  
4.1 Immunotherapy: cancer and beyond  
 
Attempts to harness the power of the immune system to fight disease have been on the forefront 
of biological and clinical research for the over two decades. T cells, in particular, are being 
exploited for their natural ability to recognize foreign antigen and initiate immune responses to 
them. The specificity of T cells can be engineered and redirected towards the detection of cell-
markers associated with a number of diseases and genetic deficiencies, including cancer.  
 
Among others, immune checkpoint blockade therapy and Chimeric Antigen Receptor (CAR) T 
cell gene therapy have drawn significant attention for their success in clinical trials. Both 
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methods rely on modifying a patient’s immune system such that it recognizes and inhibits tumor 
growth. In particular CAR T cell immunotherapy has been effective in clearing certain blood cell 
tumors in a number of patients. Additionally, CARs have been designed and tested for other 
clinical indications such as neurological diseases (Parkinson’s Disease, Alzheimer’s Disease)89, 
as well as in treatment of HIV90, 91. CARs are synthetic recombinant receptors designed to 
specifically target a particular antigen. They encompass a combination of moieties that enable 
antigen recognition/binding (Single-chain variable fragment (scFv)), T cell activation (CD3ζ 
chain), and co-stimulation (CD28 or 4-1BB, among others) to create a functional response in 
CAR-expressing T cells92. While many methods of genetic modulation have been employed to 
insert the CAR into the genome, so far, one of the most prevalent successful mechanisms is via 
lentiviral vector mediated gene delivery. Although most work has been done in lentivirus, other 
viral vector systems exist and each presents its own advantages and limitations (Figure 13).  
 
 
Figure 13. Viral vectors used in gene therapy.  
Vectors have been derived from a number of viral systems including Retrovirus, Herpesvirus, 
Adenovirus, and Adeno-Associated Virus.  Table provides key characteristics and properties of 
each system. (Adapted from Kalburgi, et al. Discovery medicine 15.81 (2013): 111-119.) 
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For example, while Adenovirus can hold up to 36kb of DNA, it is only suitable for therapies that 
require transient expression, as the virus is non-integrating93. Adeno-Associated Virus (AAV) 
provides stable expression, but is limited in terms of the amount of exogenous DNA able to be 
packaged into the vector94. Retroviruses have been utilized for CAR T cell therapy as well as for 
targeting dendritic cells95, but rely on a mitotically dividing population for gene delivery. On the 
other hand, lentiviral particles have the ability to infect both dividing and non-dividing 
populations, and have been extensively modified for safety and efficacy96. Here, we specifically 
discuss lentiviral vectors for their ability to transduce non-dividing hematopoietic stem cells in a 
therapeutic setting.  
 
4.2 Lentiviral gene components and vector structure 
 
HIV-1 is a single-stranded RNA lentivirus. Upon reverse transcription, the viral DNA can be 
integrated into the host genome. The HIV-1 genome contains 9 genes which span over ~9kb and 
encode a variety of structural, regulatory and accessory proteins. Flanking the viral coding 
regions are cis regulatory elements such as long terminal repeats (LTR), a packaging signal (Ψ) 
and a rev response element (RRE).  
 
Gag and pol are translated into precursor proteins, which give rise to the core structural and 
transcriptional proteins of the virus. Proteolytic cleavage of Pol yields proteins PR (protease), RT 
(reverse transcriptase) and IN (integrase). The protease activity of PR is responsible for the 
processing of both Pol and Gag into their final products. RT reverse transcribes the viral RNA 
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genome into DNA for integration into the host genome by IN. Gag precursor is further processed 
into matrix 10, capsid (CA), nucleocapsid (NC) and p6 proteins, which are essential for the 
formation and infrastructure of the virion as well as post-entry and viral release steps. 
 
Envelope glycoprotein (env) also encodes a precursor protein (gp160) which is proteolytically 
cleaved into two surface proteins: gp120 and gp41. Both are essential for effective host-receptor 
binding. In particular, gp120 mediates the binding to the CD4 receptors on T cells and 
macrophages97. Upon binding and attachment, the host cell membrane fuses with the viral 
membrane, and viral entry is facilitated via gp4197.  
 
Transactivator (Tat) and Rev are involved in the enhancement and regulation of transcription. 
Flanking the viral genome on the 5’ and 3’ ends are Long Terminal Repeats (LTR). Within LTR 
regions exist promoter and enhancer sites that are essential for viral transcription. The LTR also 
functions in viral integration into the host genome as well as polyadenylation of viral RNA.  
LTRs alone, however, are inadequate for effective transcription and must work in conjunction 
with Tat to promote production of viral transcripts (and ultimately proteins). Additionally, Rev 
binds to the Rev-responsive element (RRE) to enable nuclear export of unspliced transcripts 
required to produce some HIV gene products. 
 
In addition to the genes that encode the structural and transcription-regulating proteins, HIV-1 
possesses four accessory genes that improve viral infectivity. Accessory proteins act to degrade 
host immune responses as well as to boost viral ability to invade and propagate within cells. The 
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optimization of current lentiviral gene therapy strategies has allowed for the exclusion of these 
genes from vectors. Efficacy and safety are improved in their absence.  
 
Gene therapy is reliant upon the ability of the viral vector to enter and integrate into host cells. 
The endogenous Env protein product, gp120 has specific affinity for CD4+ cells. The use of 
gp120 to form the envelope can result in pathogenic consequences, and can also limit the 
potential pool of patient cells that can be infected by gene therapy vectors. As such, heterologous 
envelopes that allow for a greater diversity of host cell infection can be used.  This is referred to 
as pseudotyping. Vesicular stomatitis virus glycoprotein G (VSV-G) is now commonly used in 
lentiviral gene therapy vectors. VSV-G is more stable than other retroviral envelopes and can 
transduce a wider array of cells including HSCs, with high efficiency98.  
 
In addition to altering vectors by pseudotyping to generate a more robust transduction, other 
modifications must be made to ensure safety. As previously mentioned, the viral genome is 
flanked by 5’ and 3’ LTRs, which contain strong enhancers. Upon transduction, a potential 
consequence of random integration into the host genome is that LTRs may activate nearby genes, 
including proto-oncogenes. Self-inactivating (SIN) vectors have been designed to reduce the 
possible occurrence of vector-mediated oncogenesis. SIN vectors lack the U3 portion of the 3’ 
LTR, which results in an inactivation of transcription in viruses. Furthermore, viral genes are 
delivered in separate vectors to decrease the probability of recombination that could result in 
active HIV-1 viruses. In this system, required HIV genes for viral expression and envelope 
assembly are placed into different vectors99, 100, 101. A third transgene-bearing vector is also 
introduced. Many vector systems have included central polypurine tract (cPPT) to increase 
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transduction efficiency102 as well as Woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE) for enhanced transgene expression103. 
4.3 Use of LCR components in lentiviral gene therapy 
 
Lentiviral vector gene therapy has proven a safe and efficacious gene transfer technology, and 
has therefore been used in many successful clinical trials. Because of the SIN modifications that 
rendered the vectors devoid of many of their own regulatory elements (LTR, promoter, 
enhancer), lentivirus has gained favorability over retroviruses for decreased insertional 
mutagenesis. Lentivirus still does, however, tend to favor genomic ‘hot spots’ along gene bodies 
rather than the retrovirally-favored regulatory elements104. Due to their ability to integrate fairly 
randomly within the genome, therapeutic genes delivered via these vectors require another level 
of regulation to ensure predictable and innocuous gene expression patterns.  
 
One of the first major steps towards the utilization of gene regulatory elements in gene therapy 
was demonstrated in a mouse model of β-Thalassemia using the β-globin LCR30. In similar 
fashion to the T cell receptor, β-globin expression is regulated by an LCR that spans 20kb in its 
endogenous locus14, 105. Of the 5 DNase I hypersensitive sites that encompass the β-globin LCR, 
some were functionally characterized, and portions of those were incorporated into lentiviral 
vectors to assess whether they could restore β-globin levels to physiological levels. A ‘mini-
LCR’ containing ~1kb of three core HS sub-elements was first tested, and found to yield 
insufficient β-globin expression, whereas incorporation of additional DNA sequence from these 
HS enabled predicted LCR activity30.  
 
42	  	  
Elements of TCRα LCR in the context of gene delivery vectors could also be used to drive 
predictable expression of therapeutic genes, or CARs in clinical settings. The precedent set by 
the success in the β-globin field has paved the way for the use of regulatory elements, and the 
characterization of TCRα mini LCR cassettes make their incorporation into viral vectors a 
logical progression in translating these studies. Thus, lentiviral packaging and transfer vectors 
were acquired from the Sadelain group at MSKCC, and modified by Dr. Armin Lahiji to include 
the TαLCR4.0 or TαLCR 1.3 mini LCRs (Figure 14).  
 
Figure 14. Lentiviral vectors for gene delivery.  
pCMVR8.9101 includes Gag, Pol, Tat and Rev genes, which are required for viral packaging. The 
pMD.G99 envelope vector encodes a pseudotyped VSV-G envelope protein, for wider cell 
affinity. A transfer vector construct bearing a transgene linked to a mini-LCR is included in 
vector flanked viral LTRs (SIN). This vector also encodes a transduction marker (NTP) as well 
as elements that enhance transduction and transgene expression (cPPT, WPRE, respectively). 
 
The transfer vector was constructed to include mini LCR constructs linked to a yellow 
fluorescent protein (YFP) with a T-cell specific Vα promoter, that is detectable using flow 
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cytometry. A modified Low Affinity Nerve Growth Factor Receptor (LNGFR) protein, or NTP 
driven by a human phosphoglycerate kinase 1 (hPGK) promoter serves as a transduction marker, 
as it traffics to the cell surface and can be tracked using flow cytometry as well. It was confirmed 
that both NTP and YFP were expressed when vectors were transfected into a mature T cell line 
(VL3-3M2), thus ensuring that the components of the LCR do not interfere with NTP expression 
(Lahiji and Rist, unpublished data). Along with the transfer vector described above, two other 
vectors containing the aforementioned essential viral elements (pCMVR8.9, pMD.G) can be 
transfected into 293T cells and tested for packaging and transduction ability, as well as for the 
ability to drive transgene expression in a TCRα-like manner.   
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4.4 Transfection, transduction, and packaging of lentiviral particles 
 
 
Figure 15. Overview of viral production assay.  
Co-transfection of viral vectors into a packaging cell line (293T) allows for viral assembly, after 
which they emerge from cells into supernatant, which is collected and concentrated. The 
resulting virus-containing solution is used to transduce target cells, after which cells can be 
analyzed for successful infection via flow cytometry. 
 
In order to test whether the minimal elements of the TCRα LCR in the context of lentiviral 
vectors could confer the predicted patterning of gene expression, the transfer vector, along with a 
packaging vector, and envelope vector were co-transfected into HEK-293T cells. As a 
transfection control, a sample transfected with a transfer vector containing only hPGK-GFP was 
tested as well. 24 hours post-transfection, roughly 80% of cells should be GFP positive, 
indicating DNA uptake by cells (cells viewed under fluorescent microscope and roughly scored 
for GFP expression, data not shown). Transfection was optimized by testing Hepes-Buffered 
Saline (HBS) with calcium chloride, Lipofectamine, or polyethylenimine (PEI) transfection 
45	  	  
methods.  48 hours post-transfection, viral particles should begin to emerge from cells, and virus-
containing media is collected. To concentrate the virus, two different methods were employed; 
ultracentrifugation and polyethylene glycol (PEG) precipitation. The concentrated virus can then 
be serially diluted and used to transduce other cells and to determine viral titers (Figure 15). 
 
After optimizing transfection protocols to yield a high percentage of GFP positive cells, it 
became evident that there existed either an inability of the virus to properly package, or to be 
transduced. This was hypothesized after an experiment in which both a GFP control transfer 
vector, as well as an LCR-bearing vector, were transfected, and concentrated media was used to 
transduce 293T cells. Whereas there was signal in the control, the samples from cells transduced 
with lentivirus containing mini LCRs were devoid of NTP expression (Figure 16).  
 
There are a number of elements within the mini LCR-containing transfer vector including the 
mini LCR might not be amenable to these processes. Elements within the LCR sequence itself, 
or other sequences unique to the LCR-containing vectors, such as the SV40 polyadenylation 
sequence106, 107, and YFP transgene were replaced in order to assess whether any of these 
Figure 16. Reporter expression 
with increasing concentration of 
virus in cells transduced with 
control, and LCR-bearing lentiviral 
vector.  
(A). Control virus, containing only 
GFP, produced signal that 
increased when transduced with 
increasing concentration of virus. 
(B). With LCR-bearing vectors, 
transduced cells failed to express 
the NTP transduction marker, 
regardless of viral concentration 
used to transduce.  
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impacted viral production. There is data to suggest that viral packing is dependent upon the 
secondary structures formed by the viral RNA108. These structures can be impacted by 
incorporation of intronic, alternative splicing, or polyadenylation sequences within viral 
vectors107, 109. If, indeed, such inhibitory variables are present, viral production would be 
impeded and might result in low titers.  Therefore, in accordance with data published from the 
Sadelain group, we sought to build new vectors with varying modifications to ensure the 
production and transduction abilities of lentiviral particles made from these vectors. It has been 
observed that YFP could be silenced through differentiation, potentially because of its genomic 
configuration and non-mammalian origins (Lahiji, unpublished data). Thus, we first generated a 
vector with a Vα-driven CAR (anti-CD19), which has not only been established as a gene that 
can be expressed through differentiation in mammalian cells110, but has also been heavily utilized 
in eight recent clinical trials for gene therapy111 (Figure 17B). 
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Figure 17. Modified viral transfer vectors.  
(A). Vector containing a mini LCR linked to a Vα-driven YFP transgene, along with human 
PGK-driven NTP transduction marker. (B). To utilize a clinically relevant transgene that has 
been established through the differentiation process as well as in clinical trials, a CAR-GFP 
replaced the YFP transgene. (C). To test whether the polyA tail associated with the transgene   
could improve viral production, an established bovine growth hormone polyA tail took the place 
of the existing SV40 polyA.  
 
Utilization of a CAR would render vectors more translationally relevant, especially if linking it 
to the LCR could ameliorate some of the current limitations in gene silencing and variegated 
expression patterns112. It has been shown that viral RNA production is impacted by orientation of 
polyadenylation sequences associated with the gene106, 107. The SV40 polyA of the YFP 
transgene contains both sense and anti-sense polyadenylation sequences, corresponding to both 
early and late polyadenyation signals. Indeed, the third AATAAA appears to be part of the 
functional late SV40pA, which could result in decreased viral RNA production. The SV40 polyA 
of YFP was therefore replaced with the bovine growth hormone (bGH) polyA tail, which has 
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been utilized and established in lentiviral production113, 114 (Figure 17C). Alternatively, it is 
possible that inhibitory sequences within the LCR itself exist, and interfere with lentiviral 
packaging. In the case of the β-globin LCR, such sequences were mutagenized, resulting in 
higher viral titers109. Many of the described inhibitory sequences that resided in the β-globin 
LCR were also found in a scan of TCRα LCR constructs (Figure 18). As such, it is plausible that 
LCR constructs might be refractory to viral RNA transcription, or packaging, resulting in very 
low, or undetectable titers.  Sites encoding reverse polyadenylation sequences, and splicing 
signals, in which these sequences are found could be mutagenized, as was done in the case of the 
β-globin LCR, to alleviate the inhibition that potentially could arise as their consequence.   
 
 
Figure 18. DNA sequences within TCRα LCR that might result in viral instability and low titer.  
Select A/T-rich regions, reverse polyadenylation signals and splice sites that were identified 
within the β-globin LCR were mapped onto TCRα LCR sequences incorporated into lentiviral 
vectors. These sequences might result in viral instability or low viral titers.  
 
Thus, a set of new transfer vectors was made to accommodate for all of the possible iterations 
that could impact packaging and production of lentivirus. The initial transfer vector (Lahiji 
thesis, 2013) contained a Vα-driven YFP transgene linked to the mini LCR. To address the 
potential inability for a YFP reporter to be (a) expressed in a mammalian system and (b) undergo 
and be expressed through differentiation, it was replaced by an anti-CD19 CAR, generously 
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provided by the Sadelain lab. Alternatively, the YFP might be amenable to the above conditions, 
but might be negatively impacted by SV40 polyA sequences, which are shown to be refractory to 
viral RNA transcription and packaging106, 107. A bGH polyA tail replaced the SV40, and was 
linked to the mini LCR-YFP cassette. Each of the newly cloned constructs was tested in the viral 
production assay.  Following transfection, fluorescent microscopy was used to detect GFP/YFP. 
Upon confirmation that the DNA had been taken up by cells, we chose to proceed using the PEG 
precipitation to concentrate viral particles, from which we would make the dilutions for viral 
titering. Various concentrations of virus were used to transduce, in 293T, 3T3, HeLa, and VL3 
cell lines. In 293T and HeLa cells, we assessed for presence of the transduction marker, NTP, 
using flow cytometry. We were unable to test for YFP expression since it is driven by a Vα 
promoter, which is T cell specific. In the T cell line (VL3), however, we were able to look at 
both NTP and YFP expression.  
 
Along with the transduced cells, a non-transduced cell population was run through flow 
cytometry as a negative control for the NTP marker. After gating on NTP, histograms for 
transduced cells were overlayed with non-transduced cells. Dilutions ranged from 1:10-
1:100,000, as well as a sample in which undiluted viral media was added to cells. Viruses 
contained either GFP only (control), YFP-SV40pA, or YFP-bGHpA. Results from the 
transductions seemed to yield a marked shift in NTP expression between non-transduced and 
transduced cells, regardless of the dilutions (Figure 19). In order to confirm the FACS findings, 
we visualized the cells using fluorescent microscopy with the help of the Feinstein and Bratu 
Laboratories, Hunter College. The results of the cell imaging were consistent with the results of 
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FACS, showing a majority of the cells appeared to be GFP or PE positive, though background 
auto-fluorescence is suspected to have led to this appearance (data not shown).  
 
We further sought to transduce a DP T cell line with the viruses in order to be able to visualize 
YFP expression, since it is linked to a T cell specific promoter, and thus only expressed in T 
cells. In cells transduced with undiluted virus of all the vector types, there was a positive signal 
in the FITC channel, indicating YFP or GFP (from a positive control vector, pRRL GFP) 
expression (Figure 19B). We also assessed for NTP expression, and found an increase in 
expression in all samples of roughly equivalent amounts, including the negative control, which 
contains no NTP (Figure 19A). Because the NTP-free control yielded a similar signal to that of 
the experimental samples, the results were questionable, and any positive signal could be 
attributed to high background.  
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Figure 19.Transduction in VL3 double positive T cells to assess NTP and YFP expression.  
Control vector, containing only GFP driven by hPGK promoter (pRRL GFP), as well as pRRL 
SV40pA (containing a Vα promoter driving YFP containing an SV40pA linked to TαLCR4.0), 
and pRRL bGHpA (containing a Vα promoter driving YFP containing an bGHpA linked to 
TαLCR4.0) vectors were used to transduce VL3 cells, and were analyzed for NTP expression. 
pRRL GFP, despite containing no NTP, produced a similar signal to that of pRRL SV40 polyA, 
and pRRL bGH polyA in undiluted samples. (B). The same samples were assessed for YFP 
expression, and pRRL GFP control, pRRL SV40, and pRRL bGH vectors produced similar 
signals in both undiluted and diluted viral transduction. 
 
 
In order to account for potential background signal coming from the experimental process and 
reagents, we introduced two controls to experiments. Both controls were designed to eliminate 
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any variable coming from reagents that might yield a positive signal. The first was a mock 
transduction control, in which samples underwent mock transfection, concentration with PEG, 
and transduction. In this way, any potential fluorescent signal emerging from reagents (PEG) 
would be incorporated into the background, and only signal resulting from transduction would 
yield a shift beyond that fluorescence.  A second control included using the mock experimental 
supernatant as the diluent for transduction. Whereas dilutions for viral titrations were initially 
made using media, mock supernatant was now used to account for any differences in 
fluorescence that might be produced by the reagents or procedural events, in attempt to 
normalize results and yield accurate readings of transduction efficiency across varying dilutions.  
Even with the newly controlled set of experiments, however, there was no change in background 
levels. pRRL GFP, should not yield any signal at all in the PE channel, since it does not contain 
the NTP transduction marker. The positive signal in the NTP channel of similar strength to that 
of the GFP signal seemingly invalidate the result.  Perhaps by transfecting more cells, and 
producing more virus-containing supernatant, higher viral titers can be achieved such that the 
positive signal will be distinguishable from that of the background. Once this is optimized, the 
differences conferred by incorporating either SV40pA or bGHpA can be determined. Once tested 
in cell lines, and viral titers are calculated, it will be possible to test viral vectors in HSCs derived 
from mouse bone marrow, or in mESCs.  
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Chapter 5: Beyond the bench: an Innovation Corps experience  
5.1 The business of science: immuno-oncology and CAR-T treatment 	  
The immuno-oncology (IO) field, at present, comprises a handful of dominant therapies, such as 
vaccinations, monoclonal antibody, checkpoint inhibitor, and CAR-T therapies, among others. 
Together, they constitute a vast and growing market, which is predicted to reach 100 billion 
dollars by the year 2020 (Global & USA Cancer Immunotherapy Market Analysis to 2020 
report).  This space is occupied by a number of key players that span the academic and industry 
spectrum. It is the synergy of high-quality, paradigm-shifting science, with ample resources that 
continue the flow through the IO pipeline.  
      
 
Partnerships between academic institutions with ‘big pharma’ and emerging biotech companies 
have become one of the leading models in generating hypothesis-driven clinical trials.  Many 
scientists are classically trained to design and execute experiments with no context of clinical 
Figure 20. Clinical phase 
distribution of IO assets.  
While IO research can be 
funded at any stage of the 
clinical trial process, 63% of 
projects are funded at the early 
stage, involving more risk, but 
more promise. This is 
especially pertinent to research 
emerging from academic 
institutions.    
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trial development, and therefore require external expertise and capital to move discoveries to the 
clinic. Partnerships or acquisitions can occur at different stages of project development, however 
the IO space, in particular, many deals occur in early-stage technologies in the pre-
clinical/research project phase (Evaluate Pharma, DH analysis) (Figure 22).  
 
The advent and success of CAR T therapy has yielded unprecedented results in recent years. As 
per a Cancer Research Institute database generated in September 2017 (Shalabi and Lucey 
ESMO 2017), over 290 CAR T therapies were being developed, with over 160 of them being 
tested in the clinic. CD19 has been a popular target, as it has proven effective in patients with 
Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin’s Lymphoma (NHL), and Chronic 
Lymphocytic leukemia (CLL)39, 115, 116, 117. In five trials, between 70-94% of patient participants 
suffering from ALL or NHL achieved a “complete response”, or disappearance of all signs of 
cancer in response to the treatment (National Cancer Institute) (clinical trials (NCT00968760, 
NCT01865617, NCT01815749, NCT01626495, NCT01044069)44. The results for CAR T in 
hematological malignancies are encouraging, likely owing to the accessibility of the liquid 
tumors to the circulating CAR T cells. Thus far, the FDA has approved two CAR T cell based 
therapies designed against B cell tumors; Kymriah (tisagenlecleucel, Novartis, 2017) and 
Yescarta (axicabtagene ciloleucel, Kite Pharma, 2017), but other B cell antigens are being 
targeted in other pre-clinical models in hopes of continued success. Efforts to generate therapies 
that can target solid tumors have been met with more hurdles, some of which include T cell 
homing to tumors, and tumor microenvironment. Other efforts to generate “off the shelf” 
therapies (Cellectis, Celyad), which would utilize allogeneic cell sources seem feasible, but run a 
55	  	  
risk of graft-versus-host disease.  This technology would, however, render the therapy much 
cheaper, as it eliminates the requirement for individualized manufacturing.  
 
Immunotherapy, as it stands at present, involves intricacies, costs, and challenges. Further 
progress will necessitate the integration of biological and medical data, and efficient clinical 
development. From the perspective of innovative trial design, strategies for evaluation, improved 
tools and manufacturing capabilities, as well as exploiting big-data target mining, and creating 
relevant pre-clinical humanized models that can inform trials are the next necessary steps. The 
understanding of the underlying basic biology that governs the mechanisms of action will shape 
the design and execution of safe, targeted, and effective gene therapy administration. 
 
The basic biology of gene regulation, in particular, can be applied to address the current state and 
limitations of immunotherapy. Specifically, the main obstacles to clinical benefit of these 
therapies include the durability of the treatment, and associated toxicities. The durability of the 
treatment might result from the exhaustion118 and/or loss of modified T populations over time, or 
from the inactivation of the therapeutic gene via epigenetic silencing. Engineering stem cell 
populations with therapeutic genes can give rise to a renewable source of T cells containing the 
therapeutic gene product over the lifetime of the patient. However, stem cell populations, such as 
HSCs can give rise to all blood cells, which can potentially result in therapeutic gene expression 
in multiple cell lineages, and at unspecified developmental stages. While it has been suggested 
that expression in earlier-derived cells, such as NK cells, can yield a “fast response” before T 
cells emerge from HSCs119, ectopic expression of TCRs either in premature T cells42 or in non-T 
cells41 has been shown to be deleterious, or lead to a block at early stages of T cell development, 
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thus requiring tight spatiotemporal regulation from transduced cells. Moreover, equipping such a 
wide array of cells with reactive potential, potentially beginning in lineages as early as stem cells 
can result in an inflammatory environment, and intensify treatment-associated toxicities. 
Additionally, subjecting a transgene to the dynamic chromatin landscape can lead to its 
extinguished expression over the course of differentiation, even in the presence of constitutively 
active promoters. Either loss of engineered T cells and silencing over differentiation can 
diminish therapeutic benefit over time, and might necessitate another round of patient treatment. 
At present, toxicities such as Cytokine Release Syndrome, which is characterized by elevated 
levels of pro-inflammatory cytokines, interferon-γ, and macrophage activation39 can be treated 
with corticosteroids, which can limit the efficacy of immunotherapy. CRS can be life-threatening 
and must therefore be managed effectively; symptoms must be controlled without compromising 
T cell activity. It was more recently reported that an IL-6 blockade could also be used without 
significantly impacting therapeutic T cell function (CD19-Redirected Chimeric Antigen 
Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of 
Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 
Antagonist Tocilizumab (toc). Grupp, et.al.,	  54th ASH Annual Meeting and Exposition; Atlanta, 
GA. 2012.). It should be noted, however, that complete response (CR) rates of patients is 
associated with degree of CRS.  
 
Given the above parameters, it seems necessary to properly modulate and insulate the expression 
of a therapeutic gene in space and time.  Conferring a therapeutic gene, such as a Chimeric 
Antigen Receptor, with the proper TCRα-like patterning can potentially restrict CAR expression 
to T cell progeny of HSCs, in a high-level, predictable manner. Importantly, the ability to 
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regulate a CAR in a natural TCRαβ-like manner can yield higher efficacy, or even reduce CAR-
related toxicity, such as CRS. A study that examined the function of a CAR targeted to the TCR 
locus, placing it under its endogenous regulatory elements, found that there was reduced tonic 
signaling as well as reduced T cell exhaustion, but improved overall efficacy of CAR T cells120. 
This highlights the importance of using cis elements, like the TCRα LCR, in order to provide a 
more well-characterized and predictable therapeutic product. As demonstrated, mini LCR-driven 
reporter genes are expressed in T cells regardless of their genomic integration site, at the correct 
stage of development. Moreover, modulating therapeutic gene expression in physiological 
TCRαβ-like fashion can reduce or prevent toxicities such as CRS altogether, eliminating the 
need for additional drugs that might inhibit the initial therapeutic benefit. 	  
 
5.2 CisTar: A novel gene regulatory platform for stem cell based therapies  
 
The ability of the TCRα LCR to modulate the expression of a linked gene in a way that is 
position independent, copy-number-related, and with the spatiotemporal specificity pattern of the 
TCRα gene, makes its use in CAR T therapy seemingly appealing and suitable. The generation 
of mini LCR cassettes that are able to recapitulate full LCR activity makes this system further 
amenable to a gene therapy setting. The largest of the mini LCR constructs, TαLCR4.0, retains 
TCRα-like expression patterns, even when reduced by ~70% of the full-length LCR. This 
“downsizing” enables its use in the context of lentiviral gene delivery vectors. Linking this mini 
LCR to a CAR would confer TCRα-like regulation, and could therefore add a layer of safety that 
could prevent some of the side effects currently associated with uncontrolled, and unpredictable 
regulation of therapeutic genes. Specifically, this linkage could prevent malignancies associated 
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with ectopic expression of the engineered gene41 and also positively impact the duration of the 
therapeutic response. Moreover, the even smaller TαLCR1.3, retains its ability to overcome 
position effects, but confers only partial copy number dependence and is expressed in monocytes 
(and perhaps other tissues that have not yet been tested). Nevertheless, this version of the mini 
LCR can still be useful in other capacities, such as in HIV therapy, since HIV can infect both T 
cells and monocytic populations121. There is evidence that suggests that is possible to make T 
cells or monocytes resistant to infection by HIV by producing therapeutic siRNA122 or 
proteins123 that disrupt HIV-co-receptor binding. Driving the T cell or monocyte-specific 
expression of these gene products would be made possible by linking them to TαLCR1.3. Other 
mini TCRα LCRs could potentially be constructed that would have varying specificities that 
might render them appropriate to drive expression in other predictable patterns appropriate for 
other T cell immunodeficiencies. Engineering T cells to express correct copies of otherwise 
mutated genes can address T cell diseases such as SCID, which results from mutations in genes 
(such as ADA, Jak3) that impact T cell development and function124. The ability of the LCR to 
drive restricted spatiotemporal patterning of an associated gene can allow for its use in stem cell 
based therapies to specify expression to a particular type(s) of progeny cells. This property can 
enable a stable, renewable therapeutic source, which can reduce the need for reinfusion in 
patients. 
 
Given the current recognition of Chimeric Antigen Receptors in immunotherapy, as well as a 
basic understanding of the gene regulatory landscape that modulates T-cell receptor expression, 
it would be interesting to apply the scientific knowledge to a relevant clinical system. Harnessing 
the ability to potentially remedy pitfalls in gene therapy would be useful to patients, physicians, 
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and even commercial producers of gene therapy. As we recognize the commercial potential of 
the study, we applied to the National Science Foundation (NSF) Innovation Corps (I-Corps) 
program, with the goal of understanding the viability of the lab’s intellectual property (IP) to 
launch a startup company. I-Corps is designed to help scientists assess and realize the 
commercial feasibility of innovations emerging from their research by intensive training from 
industry leaders as well as the ‘get out of the building’ method, in which interviews are 
conducted with key opinion leaders (KOL) in the field. Further, the New York City Innovation 
Node (NYCRIN) branch of I-Corps aims to enhance the biotech ecosystem in New York and the 
surrounding regions by fostering a strong network for growth and development. Gayathri 
Raghupathy and I assumed positions of entrepreneurial leads (ELs), with Dr. Ben Ortiz as 
principal investigator, and Dr. Eric Vieira as our industry mentor. Based on Steve Blank’s Lean 
Startup plan, which emphasizes evidence-based entrepreneurship, we constructed a testable 
business hypothesis, and tracked our ‘data’ on a business canvas model. The business model 
includes nine key channels that help entrepreneurs test the components of their central business 
hypothesis, including customer segmentation, partners, resources, revenue streams, and value 
proposition (Figure 23). Initially, the canvas was populated with a narrowly scoped technology 
aimed only at clinicians, but evolved over the course of the I-Corps journey to use mini LCRs as 
a platform technology, that can be multi-purposed and made-to-order for various disease 
indications. This journey was mainly guided by our in-person customer interviews that informed 
each change along the way.  
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Figure 21. Business model canvas.  
The business model canvas is segregated into nine channels, which are populated by 
entrepreneurs to focus plans and customer interviews. The evolution of the canvas over I-Corps 
reflects pivots and fine-tuning, emerging from discussions with potential customers. Channels 
include Key Partners, Key Activities, Value Propositions, Customer Relationships, Customer 
Segments, Key Resources, Channels, Cost Structure, and Revenue Streams.    
 
What we discovered through interviewing 47 KOL was that the CAR T technology was faced 
with some main challenges: (1) Safety, (2) Ability to prepare a ‘universal donor’, (3) Cost and 
efficiency, (4) Expansion to a wider set of indications and targets (solid tumors, etc.), and (5) 
Overcoming the tumor-suppressive microenvironment. The mini LCR platform could address 
some of the current challenges, and help progress the field of gene therapy.  
 
Along the lines of safety, there have been major toxicities associated with the therapy that have 
caused substantial hurdles to FDA approval and use in the clinic. The two main concerns are 
associated with on-target, off-tumor effects, and cytokine storms. On-target, off-tumor effects 
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can occur when the CAR is driven to an antigen that is not exclusive to the cancer cell. For 
example, the highly popular anti-CD19 CAR has been shown to result in B cell aplasia in 
patients115 116, as well as the anti-ERBB2 CAR that targets her2, which can be expressed in non-
tumor tissues such as heart and lung125. The identification of more specific targets that are 
restricted to tumor tissue is therefore being highly prioritized in the field. Cytokine storms refer 
to the “immune Armageddon” that cause high fevers, hypotension, and potentially even organ 
failure in patients receiving T cell therapies. These side effects are thought to be caused by the 
high number of activated T cells infused into the patient39, 115, 126 as well as high tumor burdens.  
 
So far, the data regarding T cell persistence is highly variable, ranging from weeks to years. 
Ideally, a balance can be achieved such that safety is uncompromised by longevity of engineered 
T cells, but that patients do not need to be re-infused with therapeutic cells numerous times, as 
this negatively impacts both cost and efficiency of treatment. Since the LCR has shown to 
possess the ability to restrict linked gene expression to T cells, if a construct were to be 
introduced to a hematopoietic stem cell population, therapeutic gene expression should be 
limited to only T cell progeny of HSCs. This would provide a renewable pool for the treatment, 
and potentially avoid the necessity for re-infusion. Additionally, the LCR has the ability to 
regulate two flanking genes at the same time, in the context of a BAC127. A “suicide gene” can 
also be linked to the LCR to enable the ability to mediate discontinuous therapy, which can 
prevent excessive cytokine release, via intermittent activation of drug-induced apoptosis in 
engineered T cells128. The suicide gene most classically tested in humans is the Herpes Simplex 
Virus- derived thymidine kinase (TK) gene, wherein upon administration of Ganciclovir, cells 
expressing this gene are killed129. Linking TK to the TCRαLCR could enable its expression in T 
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cells, but not in HSC reservoirs, thus eliminating active cells while preserving their stem cell 
source. Implementation of this system, wherein a mini TCRα LCR construct linked to both a 
therapeutic and a suicide gene can be transduced into HSCs, but only expressed in T cells 
emerging from the renewable stem cell pool, might limit side effects associated with treatment. 
Upon administration of TK, only actively expressing T cells will be eliminated, without 
destroying the therapeutic source. Alternatively, methods have been explored in which cells 
permanently express individual CAR components in a “split CAR design”, which do not activate 
until a small molecular enables dimerization130. This can also impose a layer of control that can 
help mitigate excessive T cell activity resulting in toxicity. 
 
There exists documentation of insertional mutagenesis resulting in malignancy in patients who 
received retrovirally-transduced HSC transplants, which caused concern about the safety of such 
treatments. While insertional mutagenesis has been documented when virally-transducing 
hematopoietic stem cell populations131, there are ways that are currently being employed to 
bypass this threat. Initial retroviral gene therapy trials in HSCs to treat Severe Combined 
Immunodeficiency (SCID) favored insertion within the LMO2 locus, a known oncogene, leading 
to tumorogenesis132. Selectively incorporating genes into “safe harbor” sites134, however, can 
achieve stable, long-term expression while preventing insertional mutagenesis. Safe harbors are 
chosen to ensure that an inserted transgene will function and not interfere with, or be interfered 
by, neighboring genes and elements, thereby reducing potential inappropriate regulatory cross-
talk or gene-disruption. In order to attain a larger pool of a potentially renewable source of cells, 
it is possible to derive patient-specific cells and induce regression into a stem cell- like lineage, 
resulting in cells called induced pluripotent stem cells (iPSCs). In the case of iPSC technology, 
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clones may be selected on the basis of possessing these characteristics, and theoretically 
expanded and re-infused into the patient accordingly. While iPSC technology is promising, it is 
not yet been approved in clinical immunotherapy models. Although we viewed insertional 
mutagenesis as a significant hurdle going into I-Corps, our discussions with leaders in the field 
of gene therapy helped us understand that this was not viewed as big of an impediment as we 
suspected, given that current therapy models (using T cells) have no evidence of insertional 
mutagenesis.  
 
Conducting interviews with clinicians and scientists in both industry and in academia helped us 
reshape our views of what some of the unmet needs in the field were, and how mini TCRα LCR 
technology could potentially close the gaps. Mini LCRs can potentially mitigate some of the 
safety risks observed by a number of current therapies. Limiting expression to T cells beginning 
at the correct developmental stage, as well as potentially incorporating intermittent treatment via 
suicide genes are some ways to increase the safety. Additionally, using HSCs provides 
renewable sinks of cells that can prevent necessity for re-infusion, maximizing efficiency and 
minimizing costs associated with production of GMP-quality cells for introduction to the patient. 
We used this guidance to steer our business model to fill the gaps in the market. 
 
5.3 Pivot! A business model for LCR-based therapies  
 
Our hypothesis was built upon the business model canvas that we generated to outline the main 
parameters that we needed to understand in order to commercialize our technology. The initial 
value proposition (VP) that we offered was a regulatory element that could offer predictable gene 
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expression that can overcome therapeutic gene silencing and reduce the toxicity associated with 
current treatment plans (see above discussion on CRS). The channels through which we could 
bring this to market were through scientists (in academia or industry), clinicians, biotech 
companies, or via research tool companies. With key resources such as IP, academic and 
industry collaborations along with the expertise in construct generation and assays; we focused 
as a research and development endeavor, aiming toward product optimization toward clinical 
trials. Additionally, we considered multiple revenue models; we could function as a start-up, 
partner with leading companies to access their technology and clinical trial know-how, or even 
license our science for royalties, milestone, or upfront payments. Given that we are a very early-
stage enterprise, it would be advantageous to gain access to resources/funding in a research 
sponsorship partnership. Partners could be academic, which would enable rapid deal structuring, 
with individuals who speak our language. These institutions, however, do not always facilitate 
commercialization and industry connections, nor do they always have the ability to fully carry 
out clinical trials. Alternatively, partnering with big pharma might allow for more rapid 
progression through trials with access to commercial operations. Partnering with industry players 
might necessitate more advanced pre-clinical data, and they might therefore prefer a less 
expensive early buy-out. Ultimately, the business plan is contingent upon the end customer. We 
aimed to primarily cater to CAR T scientists as our major customer segment (CS). What we 
learned, though, in customer interviews, was that our VPs did not necessarily match the pain 
points in the field. Whereas we believed there was a demand for ways to solve issues such as 
gene silencing, longevity, and toxicities, our customers pointed out that the current model of T 
cell gene therapy already had protocols in place that are being tweaked. For example, clones can 
be selected for favorable integration site, or, alternatively genes can be targeted into desirable 
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loci for more predictable expression120. Abrogating toxicities associated with CRS has been 
attempted utilizing management with other drugs (i.e. corticosteroids, cytokine-targeting), and 
studying its causes on a basic scientific level135, 136. To work with a different model, such as stem 
cell therapy, would create twists in the road to approval, even though it might be a better system. 
If we wanted to shift the current model, we needed more pre-clinical data, such as more in vitro 
data to validate what we have seen, as well as in vivo data in animals, and ultimately in humans, 
to justify it. The ability of mini LCRs to recapitulate hallmark LCR properties across all models 
to drive predictable and specific gene expression would be necessary in order to bring this closer 
to patient populations. We targeted a new customer segment, scientists in the biotech industry, 
who would be able to move the technology forward at a faster pace and offer efficient testing 
platforms, both in CAR T and stem cell-based therapy spaces. The two major pivots we 
experienced in VP (CAR T versus stem cell based therapy) and CS (academic to industry based 
scientists) gave us a broader scope of how to navigate the commercialization of science. It gave 
us the tools to see our technology through many lenses, and provided the opportunity to think 
about data in a new light. We needed more solid pre-clinical (animal studies) and clinical data 
(human studies) before moving more aggressively into the biotech space. 
 
5.4 Reshaping the trajectory: scientists in a new space 
 
I-Corps was a very significant player in shaping the way the research emerging from our lab 
could be understood and applied, particularly within the IO space. “Getting out of the lab” forced 
us to put our data and ideas into a wider context, and helped guide the thinking process governed 
by the interplay of science and business. Increasingly, academic labs are funded by non-
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traditional grants, often from the private sector. Speaking with leaders in science and medicine 
helped us identify the pain-points of the field, notably, the treatment of CRS, and improved 
targeting of CARs. This gave us a better understanding of how TCRα LCR can address the 
perceived limitations, in its ability to specify expression of linked genes to unique populations of 
cells in a predictable and directed manner. It is imperative to have the foresight to and wide 
scope to shape the scientific endpoint in a data-driven manner that is fitting for the current state 
of the field. We learned to move with the data, be open to pivots and shifts, and to most 
importantly let the science guide us.  
 
This training, in conjunction with formal in-lab instruction has yielded a more complete, holistic 
understanding of science. Speaking the language of biology as well as business is invaluable. 
The ability to translate science to a wide spectrum of individuals makes data more relevant, 
tangible, and far-reaching.  
 
Chapter 6: Conclusions and future directions 	  	  
The data presented here offer insight into the potential inner-workings of the TCRα LCR. Based 
on the impact of progressive deletions in mini LCR constructs, we can narrow down some of the 
properties associated with the sub-regions of HS. TαLCR4.0, despite containing only four of the 
nine HS, seemingly retains the ability to drive spatiotemporally restricted expression of a linked 
transgene in a copy number dependent manner. Based on this construct, as well as data from 
years of characterization of HS1, HS1’, HS4, and HS6, these HS are sufficient for hallmark LCR 
qualities. The generation of TαLCR2.9, introduced a deletion of HS4, and enabled us to delve 
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more deeply into HS4’s contributions function in the context of the other HS. The lymphoid-
specific hypomethylation47 and enrichment for acetylation marks137 of HS4 indicate an open 
chromatin structure in T cells. This conformation might be associated with the decrease in 
transgene expression and variegation phenotype in mice with HS4 deletions28. Interestingly, in 
the two clones tested, while the spatiotemporal restriction of transgene expression was retained, 
in mature T cells, a bimodal pattern was observed, corroborating with the in vivo data of lower-
level transgene expression. The inability of the LCR to drive high-level expression in the 
absence of HS4 can be attributed to possible position effects at the local chromatin site.  
 
The incorporation of an evolutionarily conserved human homology block found in HS4 appears 
to rescue the variegating expression of TαLCR2.9 in preliminary data from two independent 
clones. TαLCR3.0 drives robust expression of the LCR-linked transgene at the mature DP stage 
of T cell development. This expression is not activated at the early DN1 stage, nor is it switched 
on in other lineages tested.  Preliminary data from early (DN1) and Later (DP) T cells suggests 
that the homology block might restore expression patterns to those seen in TαLCR4.0, which 
might be attributed to some of the factors that are predicted to bind within the conserved 
sequence. Among these are members of the Ets and RUNT protein families, which have been 
implicated in chromatin modulation functions86, 87. Also predicted to bind to this region, in silico, 
are GATA proteins, which are key regulators of hematopoietic development138. GATA motifs 
have also been identified in the core HS of the β-globin LCR, and have been attributed as some 
of the key motifs in establishing position independence in that locus139.  These proteins, if bound, 
along with others likely help mediate the suppression of position effects, and help recover the 
loss of high- level gene expression seen in TαLCR2.9.  
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Further reduction of the mini LCR in the TαLCR1.3 cassette was endeavored by eliminating 
DNA 3’ to CTCF sites in HS1’ as well as DNA residing external to TF123 and HS316 motifs in 
HS6. Early stage (DN1) T cells emerging from differentiated ES cells transfected with 
TαLCR1.3 display premature activation kinetics, relative to the expected upregulation at the 
DN3-DP transition. This upregulation is also seen ectopically, in monocytes derived from these 
cultures. The resulting phenotype could be the product of the deletions made in either HS1’, 
HS6, or both. HS1’ is responsible for the spatiotemporal control of both distribution of LCR-
driven gene expression, as well as for the chromatin-opening ability of HS626. This ability of 
HS6 speaks to its role in suppressing position effects. In particular, TF123 contains factor-
binding sites that were identified in thymus, and the HS316 region support a more widespread 
chromatin-opening ability27. The factor occupancy in HS6, however, is dictated by the presence 
of HS1’27. These data taken together suggest an interplay between HS1’ and HS6. It is plausible 
that some of this cross-talk is mediated by the missing regions in HS1’ or HS6. Despite inclusion 
of CTCF binding sites in HS1’, which have been shown to mediate enhancer-blocking 
insulation137, but are dispensable for overall LCR activity28, promiscuous gene expression might 
be enabled by the absence of the 3’-most portion of this HS. The ~300bp of HS1’ DNA might 
play a role in either enabling factor occupancy at HS6, or by allowing for physical interaction of 
the two sites. Loss of transcription factor binding at either HS1’ or HS6 could therefore 
potentially alter the epigenetic or physical landscape of the LCR. This is especially conceivable 
since CTCF has been shown to form the 3D architecture in other loci (such as β-globin140, and 
MHC class II141) to establish stage and tissue specificity. CTCF’s role in organizing the 
landscape of the genome is often accomplished through physical interaction, which can be 
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mediated by looping with itself, or in concert with other factors, such as cohesin142. Cohesin has 
been found at HS1’137, and has also been shown to bind in the HS2-6 region of the LCR143. 
Deletion of cohesion altered TCR rearrangement143 Jα transcription, which resulted in loss of an 
activating epigenetic mark144, both impacting T cell development. Its role in the TCRα/Dad1 
locus, however, with respect to how it might facilitate tissue specific enhancer blocking remains 
unknown. A disruption of looping from loss of physical factor contact, or lack of recruitment 
could result from deletion of sub regions in this construct.  
 
Additionally, other factors might contribute to the loss of activity in TαLCR1.3. Using publicly 
available ChIP-seq databases, as well as factor binding prediction databases, we identified a 
range of factors that might bind to the 3’ end of HS1’ and the regions outside of TF123 and 
HS316 in HS6 (Figure 22).  
 
Figure 22. Predicted factor binding at HS1’ and HS6.  
Using transcription factor binding site prediction software (http://gene-
regulation.com/pub/programs/alibaba2/), selected factors were mapped onto regions of deleted 
HS sub-regions. Selected proteins were chosen based on their roles in chromatin modulation, or 
immune function.   
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Among these are factors that are known for their roles in chromatin modulation. FoxA1 has 
binding sites in the probed regions of HS6, and has been shown to modulate chromatin via 
nucleosome positioning, and has been shown to act as a pioneer factor in development145, 146. 
Ets1 also has binding motifs within regions of HS6 excluded from the mini LCR. Ets1 has been 
associated with transcriptional regulation in hematopoietic cells, and can bind directly to DNA, 
or two other factors such as p300 (bound to HS4) to mediate its function147. SP1 and Oct1 are 
well known for their roles in chromatin modulation, which can be exerted independently or 
synergistically148, 149. Predicted binding sites for both of these factors are found along the probed 
regions of HS1’ and HS6. These factors and others can impact the distribution of both proteins 
and chromatin modifications along the body of the LCR, thereby directly influencing its function 
(Figure 23). 
 
 
Figure 23. Model of sub-region interactions.  
Dark blue boxes indicate regions excluded from TaLCR1.3. We hypothesize that inter-play 
amongst these is necessary to fully recapitulate LCR activity. The 300bp region in the 3’ end of 
HS1’ might be responsible for the recruitment and binding of factors that help HS6 protect 
against position effect variegation. Additionally, the HS4 homology block seemingly restores the 
ability of the LCR to drive high-level transgene expression to the robust levels seen in the 
presence of the complete HS4.  
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Although robust, high-level expression is observed, it does fall out of the accepted range of strict 
copy-number dependence. As suggested earlier, the absence of HS4 could result in subjectivity 
to position effects, which might be manifest either by a decrease in transgene expression, or by 
loss of copy number dependence.  
 
The reestablishment of classical LCR activity could potentially be restored via the incorporation 
of either of the two missing elements in TαLCR1.3 (within HS1’ or HS6). Two “rescue” 
constructs were generated that reincorporate either one of these sub-regions: TαLCR1.6 restores 
the 3’ end of HS1’, while TαLCR2.6 contains the full HS6, rather than just TF123 and HS316. 
These constructs have already been transfected into ESCs, selected, and screened. Differentiation 
of the mini LCR bearing ESCs followed by analysis of reporter expression would yield powerful 
information on very narrow regions of the TCRα LCR, which would provide insight into 
possible mechanisms of action.  
 
Mini TCRα LCR technology would potentially offer an additional layer of specificity and safety 
to existing T cell gene therapy approaches. As the constructs stand at present, even the largest of 
the mini LCRs, at 4kb, would be amenable to insertion with a CAR into a gene delivery vector. 
With the deeper analysis of the LCR sub-regions, it is possible not only to further reduce the 
included HS, but to tailor the targeting to alternative cellular subsets, lineages, and disease 
indications. While lentiviral vectors are a traditional gene delivery vehicle, efforts to test mini 
TCRα LCR cassettes in their context require further investigation and optimization. We sought 
here to remedy the potential pitfalls resulting from inhibitory polyadenylation sequences, and 
attempted to render vectors more translatable and clinically relevant by using an established 
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CAR that has undergone the viral production assays followed by cell differentiation. It is 
possible that other variables might exist that are refractory to viral packaging and production in 
this circumstance. Lentiviruses, although conventional, are now being cited for their ability to 
stimulate adaptive and innate immune responses in recipients150. Alternative methods of gene 
therapy, such as electroporation, lipofection151, transposition133, 152, and CRISPR120, 153, are now 
more widely tested and accepted. Additionally, the advent of the aforementioned technologies 
might enable more efficient therapeutic administration along with precise targeting, and 
predictable, robust expression. It would be interesting to utilize novel methods along with mini 
LCR technology to help advance the state of gene therapy.   
 
Chapter 7: Materials and methods 
7.1 Reporter gene constructs  	  	  
hCD2ΔT84 is used as a reporter gene for all described constructs, and was excised from pBSK 
SK using Sal I and Bam HI. hCD2ΔT was linked to the full TCRα LCR, excised using Kpn I and 
Not I, and used as a positive control for experiments. To generate mini LCR constructs, various 
sub-regions derived from pLCRc were incorporated as described below. TαLCR4.0 contains 
HS1, HS1’, HS4, and HS6. PCR was used to generate the 1-kb HS1-1’ fragment, which is 
defined by its Pvu II (in HS1) to BamH I (in HS1’) borders.  An ApaL I – Dra I HS4 fragment as 
well as an Mfe I - Ecl36 II fragment corresponding to HS6 were ligated to the HS1-1’ elements 
to complete the TαLCR4.0. TαLCR2.9 was created by incorporation of the aforementioned 
segments of HS1-1’ and HS6. TαLCR3.0 was made by incorporating an HS4 homology block 
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(Figure 11) into TαLCR2.9 vector.  The HS1-1’ fragment used in TαLCR1.3 incorporates a 
~750bp region spanning from Pvu II – Sca I, as well as a 554-bp region of HS6 spanning from 
Bcl I to Bgl II. TαLCR1.6 was generated using In-Fusion cloning technology (Clonetech) by 
using PCR to yield the Pvu II- BamH I fragment corresponding to the full HS1-1’ sites and the 
554-bp Bcl I- Bgl II fragment of HS6. These elements were incorporated into a pBSK vector 
containing hCD2ΔT.  
 
7.2 ESC culture and transfection 
 
The murine ESC line, ESR1, are cultured in DMEM (Cellgro) supplemented with 20% ESC-
qualified FBS (Gemini), 1% Glutagro (Cellgro), 1% penicillin/ streptomycin (Cellgro), 1% 
HEPES (Millipore), 1% nonessential amino acids (Millipore), 0.1% gentamicin (Life 
Technologies), 0.1% β-mercaptoethanol (Life Technologies), and 10 ng/ml LIF (Millipore). 
ESCs are grown on a mitomycin-C treated mouse embryonic fibroblast (Millipore) monolayer. 
Transfection was done via electroporation (Bio-Rad gene pulser) at 0.24 kV and 500 µF. 7-12ng 
of all constructs were individually transfected along with equimolar ratios of a 1.6-kb SV40-
driven neomycin resistance cassette derived from pEYFP-C1 (Clonetech) using Ssp I and 
EcoO109 I.  Cells were allowed to recover for 24 hours post transfection, whereupon selection 
was carried out at 0.18mg/ml for approximately 10 days, when individual ESC colonies were 
picked. Colonies were expanded and propagated under selection. 
 
Screening for positive clones was done by both PCR and Southern Blot analysis. PCR primers 
were designed in the hCD2 promoter (F: 5’-GAGGAAACCAACCCCTAAGATGAG-3’; R: 5’-
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CGTAATCTCTTTGGAGACTGCACC-3’). DNA from individual clones bearing a positive 
PCR signal for hCD2 was digested using Bgl II for Southern Blot analysis to assess for 
truncations and number of integrants. An 800-bp Bgl II probe was designed to bind to the HS6 
region, as described in Harrow, et. al. 2005. Three sets of Southern Blots were done to confirm 
copy number, which was normalized to the endogenous signal from the respective clone. The 
probe design enabled detection of signal from both the endogenous TCRα locus as well as from 
the transgene such that normalization for relative copy number could be done from a single blot.  
 
7.3 ESC differentiation assay 
 
ESC differentiation to T cells, and other hematopoietic lineages (such as erythroid and 
monocytic) was done as previously described76, 154. Briefly, ESCs were plated onto an OP9-GFP 
bone marrow stromal cell line for five days, after which the emrging blood mesoderm is cultured 
along with Flt-3L (R&D Biosytems). Development progresses towards hematopoietic stem cells, 
which are harvested and distributed onto either OP9-GFP for derivation of erythrocytes or 
monocytes, or onto OP9-DL1s to drive T cell differentiation. Each co-culture was conducted 
with individual mini-LCR clones along with a non-transfected ESR1 negative clone. 
Additionally, a single copy clone bearing the full LCR was run as a positive control.  
 
7.4 Flow Cytometry  
 
Acquisition was done using the FACS Scan device. Harvested cells were Fc-blocked using anti 
CD16/32 Ab (BD Biosciences), and stained with Abs as described below. Following 20 minutes 
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of staining, samples were washed 3 times. On Day 12 of co-culture, the staining panel was 
designed to detect early stage T cells, erythroid cells, and monocytic cells. Day 16 and Day 20 
FACS detected later stage double negative as well as double positive and CD8 single positive T 
cells. FITC conjugated anti-hCD2 (clone S5.2) was used for transgene detection. Dead Cell 
Discriminator (DCD), or 7-AAD labeled dead cells. APC conjugated anti-CD45 (clone 30-F11), 
AF-700-conjugated anti- CD44 (clone IM7), PE-conjugated anti-CD25 (clone 3C7), PE 
conjugated anti-CD8 (clone 53-6.7), and AF-700-conjugated Ter119 (clone TER119) all from 
BD Biosciences, and AF-700-conjugated to CD4, and PE-conjugated CD11b  (Life 
Technologies) were used at appropriate FACS time points.  
 
Analyses were done using FlowJo software (Tree Star). Forward and side scatter plots were used 
to gate for lymphocyte populations, after which cells were further gated for negative DCD signal. 
CD45 was used to gate for hematopoetically derived lineages (except for erythrocytes, which are 
negative for CD45) in conjunction with appropriate aforementioned cell-type-specific markers.  
 
7.5 qRT-PCR 
 
Total RNA was collected from cells using Qiagen RNeasy micro kit, from which cDNA was 
synthesized (NEB Protoscript cDNA Synthesis kit). qRT-PCR was done using Dynamo SYBR 
Green qPCR kit (Thermo Fisher) on samples derived from a single well of a six well plate on 
Day 20 of co-culture in an Applied-Biosystems Viia7 Real-Time PCR machine. To calculate the 
mRNA levels, a non-transfected ESR1 was used as a calibrator, and TCRα was used as a 
reference gene. The cycle threshold (Ct) values obtained using hCD2 primers (F: 5’- 
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CCTTTCTGCTGGTGAACTTGTG-3’; R: 5’- TCAACACAACCCTGACCTGTG-3’), were 
subtracted from the Ct value calculated from the TCRα primers (F: 5’- 
AAGATCCTCGGTGTCAGGACA-3’; R: 5’- AGCAACCTTCCTCACAAATCTG-3’) to yield 
the normalized ΔCt value per clone. Each ΔCt value was then subtracted by ESR1 calibrator to 
determine the ΔΔCt. This value resulted in the normalized relative hCD2 expression level per 
clone, as calculated using the 2-ΔΔCt method. Expression levels per copy were then obtained by 
dividing by transgene copy number (Southern Blot) for each clone. Experiments were done in 
triplicates. Relative fold difference was assigned by designating the clone with the highest 
expression level as 1.0, and dividing the expression from individual clones. 
 
7.6 Viral packaging constructs  
 
To generate new transfer vectors for viral packaging, we began with an established vector 
containing an anti-CD19 CAR driving a GFP transgene. The SV40 polyA tail was synthesized 
using PCR (primers: F: 5’-GCGTCGACGCTTAAGATACATTGATGA-3’ R: 
5’AAGCTCGAGGATCCACCGGATCTA3’), and cloned into the Sal I- Xho I sites in the parent 
vector. This vector was cut using Age I- Nco I to insert the Vα promoter (F: 5’-
AAACCGGTAAGGACGGTAGCATTTTC-3’ R: 5’-GGCCATGGACCGGGAGATGTATTC-
3’) upstream of the CAR. The resulting Vα-CAR GFP-polyA cassette was excised using Bgl II 
(blunted)- Xho and inserted into pBSK cut with Sal I (blunted)- XhoI. pgkNTP transduction 
marker was liberated from the initial transfer vector using Sal I (blunted)- Xho I, and inserted 
into the EcoR I- Sma I site in the new vector, to yield a full transcription unit containing Vα-
CAR-GFP-polyA with pgkNTP in the opposite orientation. Using InFusion cloning technology 
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(Clonetech), we used PCR to pick up the entire transcription unit (F: 5’-
GAGGTTGATTGTCGACGCGGTGGCGG3-’ R: 5’-
CTCGAGAAGCTTGATTACCGGGCCCC3-’) and place it into a new third generation lentiviral 
backbone (Trono lab, purchased from Addgene) to yield the control vector. Primers were 
designed to amplify either TαLCR4.0 (F: 5’-CCGGTGGATCCTCGACTCGAGCTGCA-3’ R: 
5’-CGGGCCCCCCCTCGAGCGGCGGCCG-3’) or TαLCR1.3 (F: 5’-
CCGGTGGATCCTCGACTCGAGCTGCA-3’ R: 5’-
CGGGCCCCCCCTCGAGTACCGCGGCG-3’) for insertion into the Abs I site of pRRL-
transcription unit vector. After sequencing analysis, a mutation in the Abs I site was identified, 
such that the LCR could not be placed into the vector. Experiments with the control vector, 
however, did not yield detectable NTP expression.  
 
The original LCR-containing vectors (pRRL-LCR, Lahiji thesis, 2013) were manipulated to 
incorporate the bGH polyA in place of the existing SV40 polyA. A G-block fragment (IDT) was 
synthesized and contained the entire sequence for bGH polyA with PspX I ends (5’-
TGTACAAATTTCAGGGTGCAGCTCGAGCCATGCCTGCTATTGTCTTCCCAATCCTCCC
CCTTGCTGTCCTGCCCCACCCCACCCCCCAGAATAGAATGACACCTACTCAGACAAT
GCGATGCAATTTCCTCATTTTATTAGGAAAGGACAGTGGGAGTGGCACCTTCCAGGG
TCAAGGAAGGCACGGGGGAGGGGCAAACAACAGACGGCTGGCAACTAGAAGGCAC
AGTCGATCCCACTTGTACAGTCGATCCCACTTGTACAGTCGAGCTGCTGGGAC-3’ ) to 
be restricted with PspX I and inserted into vector linearized with PspX I. Linearizing the pRRL-
LCR with PspX I removes a portion of pgkNTP, which was restored by priming up the fragment 
from pRRL-LCR (F: 5’-CTGAAATCTTGTACAGCTCGTCCATGCC-3’ R: 5’-
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GAACACGAGGCTCGAGCCCGAGCCCGC-3’) and inserting it into the pRRL-bGH plasmid 
linearized with PspX I.  
7.7 Viral production assay  
 
Viral production was done using protocols from Sadelain Lab, MSKCC. Prior to transfection, 
293T cells were split such 80-90% confluence is achieved. 293T media (DMEM [Cellgro], 10% 
FBS [Gemini], 1% Glutagro [Cellgro], 1% Penicillin/Streptomycin [Cellgro]) is replaced one 
hour prior to transfection. A DNA mastermix is made using 10µg transfer vector, 7.5µg 
CMVΔR8.91 (encodes gag, pol, tat, rev), 2.5µg pUCMDG (encodes VSV.G envelope), 50µl 
CaCl2, up to 500µl with sterile dH2O per sample. For every 1mL of DNA mastermix, 1mL of 2X 
Hepes Buffered Saline (5M NaCl, 1M Hepes [Cellgro], 1mM Na2HPO4, up to 500mL with 
sterile dH2O, pH 7.12) is added dropwise, while vortexing.  Then, 1mL of the mixture is added 
dropwise to each 10cm dish. 16 hours post-transfection, media is replaced, and 24 hours after the 
media change is the first collection of viral supernatant (a second collection can be done 24 hours 
later). As an alternative to HBS/CaCl2 mediated transfection, Polyethylenimine (PEI, 
Polysciences, Inc.) can be done. The same ratios of viral vectors as above are mixed to create a 
DNA mastermix, along with 2mL of DMEM (Cellgro) and 70µl PEI.  
 
Media is collected 48 hours post-transfection, and can be stored at 4°C. Collected supernatant 
can be concentrated via ultracentrifugation (20,000rpm, 30 minutes, 4°C), or via polyethylene 
glycol (PEG) precipitation (Systems Biosciences), following provided protocol. Briefly, this 
entails adding 1 volume of PEG for every 4 volumes of viral supernatant, and refrigerating it at 
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4°C overnight. After spinning at 4°C for 30 minutes at 1,500rpm, a white pellet will be visible, 
and can be resuspended using PBS, aliquoted, and stored at -80°C.   
 
Transduction can be done with or without polybrene. From our experience, even small amounts 
of polybrene (ranging from 2-8µg) resulted in cell death relative to polybrene-free controls. 
Dilutions in media can be made to titrate virus in multiple wells of a 6-well plate. After 24 hours, 
media is changed, and cells can be passed, or analyzed via flow cytometry for NTP expression 
(BD, clone C40-1457) or YFP. 	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List of Abbreviations:  
 1. TCRα: T-cell Receptor α 2. LCR: Locus Control Region  3. HS: Hypersensitive Site 4. Dad1: Defender Against Death 1  5. CAR: Chimeric Antigen Receptor  6. ESC: Embryonic Stem Cell 7. LIF: Leukemia Inhibitory Factor 8. AGM: Aorta-Gonad-Mesonephros 9. HSC: Hematopoietic Stem Cell  10. MPP: Multipotent Progenitor 11. CMP: Common Myeloid Progenitor 12. CLP: Common Lymphoid Progenitor 13. Flt3 (-L): FMS-like Tyrosine Receptor 3 (-ligand) 14. MHC proteins: Major Histocompatibility proteins 15. IL7: Interleukin 7 16. DN: CD4 and CD8 Double Negative 17. CD: Cluster of Differentiation 18. DP: CD4 and CD8 Double Positive  19. SP: CD4 or CD8 Single Positive  20. TF(123): Thymic Footprint 21. CTCF: CCCTC Binding Factor 22. qRT-PCR: Quantitative Real Time- Polymerase Chain Reaction  23. LTR: Long Terminal Repeat  24. RRE: Rev Response Element 25. VSV-G: Vesicular Stomatitis Virus Glycoprotein 26. SIN: Self Inactivating  27. cPPT: Central Polypurine Tract 28. WPRE: Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element 29. LNGFR: Low Affinity Nerve Growth Factor Receptor (NTP in constructs) 30. PEG: Polyethylene Glycol  31. IO: Immuno-oncology 32. CRS: Cytokine Release Syndrome 33. IP: Intellectual Property  34. KOL: Key Opinion Leader  35. EL: Entrepreneurial Lead 36. VP: Value Proposition  37. CS: Customer Segment 	  	  	  	  	  	  	  
81	  	  
List of primers: hCD2	  promoter	  F:	  5’-GAGGAAACCAACCCCTAAGATGAG-3’	  hCD2	  promoter	  R:	  5’-CGTAATCTCTTTGGAGACTGCACC-3’ hCD2	  qPCR	  F:	  5’- CCTTTCTGCTGGTGAACTTGTG-3’	  hCD2	  qPCR	  R:	  	  5’- TCAACACAACCCTGACCTGTG-3’ TCRα	  qPCR	  F:	  5’- AAGATCCTCGGTGTCAGGACA-3’	  TCRα	  qPCR	  R:	  5’- AGCAACCTTCCTCACAAATCTG-3’ SV40	  F:	  5’-GCGTCGACGCTTAAGATACATTGATGA-3’	  SV40	  R:	  5’AAGCTCGAGGATCCACCGGATCTA3’ 
Vα	  F:	  5’-AAACCGGTAAGGACGGTAGCATTTTC-3’	  
Vα	  R:	  5’-GGCCATGGACCGGGAGATGTATTC-3’ 
Transcription unit (TU) F: 5’-GAGGTTGATTGTCGACGCGGTGGCGG3-’ 
TU R: 5’-CTCGAGAAGCTTGATTACCGGGCCCC3- 
TαLCR4.0 F: 5’-CCGGTGGATCCTCGACTCGAGCTGCA-3’	  
TαLCR4.0 R: 5’-CGGGCCCCCCCTCGAGCGGCGGCCG-3’ 
TαLCR1.3 F: F: 5’-CCGGTGGATCCTCGACTCGAGCTGCA-3’ 
TαLCR1.3 R: 5’-CGGGCCCCCCCTCGAGTACCGCGGCG-3’ 
pgkNTP replacement F: 5’-CTGAAATCTTGTACAGCTCGTCCATGCC-3’	  
pgkNTP replacement R: 5’-GAACACGAGGCTCGAGCCCGAGCCCGC-3’ 
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Table of constructs: 
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Supplementary data: 
	  
Supplementary Figure 1: Tables of Mean Fluorescence Intensity (MFI) in co-culture trials for 
mini LCR constructs. MFI values were calculated using FlowJo software (Tree Star) from 
readout on hCD2-FITC in the indicated cellular subsets. (A). and (B). Tables for TαLCR4.0 and 
TαLCR1.3 indicate MFI values obtained in three independent co-culture experiments through 
developmental stages (DN1, DN2, DN3, DP [only shown for 2 experiments]), and in both 
erythrocyte and monocyte populations. (C). Table for TαLCR2.9 indicates MFI values obtained 
in two independent co-culture experiments through developmental stages (DN1, DN2, DN3, DP 
[only shown for 1 experiment]), and in both erythrocyte and monocyte populations. (D).  Table 
for TαLCR3.0 indicates MFI values obtained  from preliminary experiments from two 
independent co-culture experiments through developmental stages (DN1, DP [only shown for 1 
experiment]), and in both erythrocyte and monocyte populations. 	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